Document:

Revolving Loan Agreement

 Exhibit 10.1 
  

 REVOLVING LOAN AGREEMENT 
 among 
 HARTE-HANKS, INC., 
 as Borrower 
 and 
 WELLS FARGO BANK, NATIONAL ASSOCIATION, 
 as Administrative Agent 
 and 
 THE LENDERS NAMED HEREIN, 
 Lenders 
 Up to $50,000,000 
 dated as of 
 January 18, 2008 
  

 WELLS FARGO BANK, NATIONAL ASSOCIATION 
 as Sole Lead Arranger and Sole Bookrunner 

 TABLE OF CONTENTS 
  

					
	 	 	 	  	Page
	ARTICLE I
	
	DEFINITIONS
			
	 SECTION 1.01.
	 	Defined Terms	  	1
	 SECTION 1.02.
	 	Terms Generally	  	11
	 SECTION 1.03.
	 	Accounting Terms; GAAP	  	12
	
	ARTICLE II
	
	THE CREDITS
			
	 SECTION 2.01.
	 	The Commitments	  	12
	 SECTION 2.02.
	 	Loans and Borrowings	  	12
	 SECTION 2.03.
	 	Requests for Borrowings	  	13
	 SECTION 2.04.
	 	Funding of Borrowings	  	13
	 SECTION 2.05.
	 	Interest Elections	  	14
	 SECTION 2.06.
	 	Termination and Reduction of the Commitments	  	15
	 SECTION 2.07.
	 	Repayment of Loans; Evidence of Debt	  	15
	 SECTION 2.08.
	 	Prepayment of Loans	  	16
	 SECTION 2.09.
	 	Fees	  	17
	 SECTION 2.10.
	 	Interest	  	17
	 SECTION 2.11.
	 	Alternate Rate of Interest	  	18
	 SECTION 2.12.
	 	Increased Costs	  	18
	 SECTION 2.13.
	 	Break Funding Payments	  	19
	 SECTION 2.14.
	 	Taxes	  	20
	 SECTION 2.15.
	 	Payments Generally; Pro Rata Treatment; Sharing of Set-offs	  	21
	 SECTION 2.16.
	 	Mitigation Obligations; Replacement of Lenders	  	22
	
	ARTICLE III
	
	REPRESENTATIONS AND WARRANTIES
			
	 SECTION 3.01.
	 	Organization; Powers	  	23
	 SECTION 3.02.
	 	Authorization; Enforceability	  	23
	 SECTION 3.03.
	 	Governmental Approvals; No Conflicts	  	23
	 SECTION 3.04.
	 	Financial Condition; No Material Adverse Change	  	24
	 SECTION 3.05.
	 	Properties	  	24
	 SECTION 3.06.
	 	Litigation and Environmental Matters	  	24
	 SECTION 3.07.
	 	Compliance with Laws and Agreements	  	25
	 SECTION 3.08.
	 	Investment and Holding Company Status	  	25
	 SECTION 3.09.
	 	Taxes	  	25
	 SECTION 3.10.
	 	ERISA	  	25
	 SECTION 3.11.
	 	Disclosure	  	25

  

 -i- 

					
	 SECTION 3.12.
	 	Use of Credit	  	25
	 SECTION 3.13.
	 	Certain Agreements and Liens.	  	25
	 SECTION 3.14.
	 	Subsidiaries	  	26
	 SECTION 3.15.
	 	Deferred Compensation and Incentive Plans	  	26
	
	ARTICLE IV
	
	CONDITIONS
			
	 SECTION 4.01.
	 	Effective Date	  	26
	 SECTION 4.02.
	 	Each Credit Event	  	27
	
	ARTICLE V
	
	AFFIRMATIVE COVENANTS
			
	 SECTION 5.01.
	 	Financial Statements and Other Information	  	28
	 SECTION 5.02.
	 	Notices of Material Events	  	29
	 SECTION 5.03.
	 	Existence; Conduct of Business	  	29
	 SECTION 5.04.
	 	Payment of Obligations	  	29
	 SECTION 5.05.
	 	Maintenance of Properties; Insurance	  	29
	 SECTION 5.06.
	 	Books and Records; Inspection Rights	  	29
	 SECTION 5.07.
	 	Compliance with Laws	  	30
	
	ARTICLE VI
	
	NEGATIVE COVENANTS
			
	 SECTION 6.01.
	 	Liens	  	30
	 SECTION 6.02.
	 	Fundamental Changes.	  	31
	 SECTION 6.03.
	 	Sale and Leasebacks	  	32
	 SECTION 6.04.
	 	Transactions with Affiliates	  	32
	 SECTION 6.05.
	 	Subsidiary Indebtedness	  	33
	 SECTION 6.06.
	 	Certain Financial Covenants.	  	33
	
	ARTICLE VII
	
	EVENTS OF DEFAULT
	
	ARTICLE VIII
	
	THE ADMINISTRATIVE AGENT

  

 -ii- 

					
	ARTICLE IX
	
	MISCELLANEOUS
	 SECTION 9.01.
	 	Notices.	  	37
	 SECTION 9.02.
	 	Waivers; Amendments.	  	38
	 SECTION 9.03.
	 	Expenses; Indemnity; Damage Waiver.	  	39
	 SECTION 9.04.
	 	Successors and Assigns.	  	40
	 SECTION 9.05.
	 	Survival	  	43
	 SECTION 9.06.
	 	Counterparts; Integration; Effectiveness	  	43
	 SECTION 9.07.
	 	Severability	  	44
	 SECTION 9.08.
	 	Right of Setoff	  	44
	 SECTION 9.09.
	 	Governing Law; Jurisdiction; Etc.	  	44
	 SECTION 9.10.
	 	Waiver of Jury Trial	  	45
	 SECTION 9.11.
	 	Headings	  	45
	 SECTION 9.12.
	 	Treatment of Certain Information; Confidentiality.	  	45
	 SECTION 9.13.
	 	USA Patriot Act	  	46
	 SECTION 9.14.
	 	Interest Rate Limitation	  	46
	 SECTION 9.15.
	 	ENTIRE AGREEMENT.	  	46

  

					
	 SCHEDULE I
	  	-	    	Commitments
	 SCHEDULE II
	  	-	    	Certain Agreements and Liens
	 SCHEDULE III
	  	-  	    	Litigation
	 SCHEDULE IV
	  	-  	    	Environmental Matters
	 SCHEDULE V
	  	-  	    	Subsidiaries
	 EXHIBIT A
	  	-  	    	Form of Assignment and Assumption
	 EXHIBIT B
	  	-  	    	Form of Opinion of Counsel to the Borrower

  

 -iii- 

 REVOLVING LOAN AGREEMENT 
 This REVOLVING LOAN AGREEMENT dated as of January 18, 2008, between HARTE-HANKS, INC., a Delaware corporation (the
“Borrower”), each Lender (as herein defined) from time to time party hereto, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent. 
 The Borrower has requested that the Lenders provide a revolving loan facility, and the Lenders have indicated their willingness to lend on the terms and conditions hereof. Accordingly, the parties hereto agree as
follows: 
 ARTICLE I 
 DEFINITIONS 
 SECTION 1.01. Defined Terms. As used in this Agreement, the following terms have the meanings specified below: 
 “ABR”, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans constituting such Borrowing, are
bearing interest at a rate determined by reference to the Alternate Base Rate. 
 “Adjusted LIBO Rate” means, for the
Interest Period for any Eurodollar Borrowing, an interest rate per annum (rounded upwards, if necessary, to the next 1/100 of 1%) equal to (a) the LIBO Rate for such Interest Period multiplied by (b) the Statutory Reserve Rate for
such Interest Period. 
 “Administrative Agent” means Wells Fargo Bank, National Association, in its capacity as
administrative agent for the Lenders hereunder and its permitted successor or successors as administrative agent for the Lenders under this Agreement. 
 “Administrative Questionnaire” means an Administrative Questionnaire in a form supplied by the Administrative Agent. 
 “Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more
intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 
 “Agreement”
means this Revolving Loan Agreement (as the same may be amended, modified, supplemented, or restated from time to time). 
 “Alternate Base Rate” means, for any day, a rate per annum equal to the greater of (a) the Prime Rate in effect on such day and (b) the Federal Funds Effective Rate for such day plus 1/2 of 1%. Any
change in the Alternate Base Rate due to a change in the Prime Rate or the Federal Funds Effective Rate shall be effective from and including the effective date of such change in the Prime Rate or the Federal Funds Effective Rate, as the case may
be. 
 “Annual Report” has the meaning assigned to such term in Section 5.01(a). 
 “Applicable Percentage” means, with respect to any Lender, (a) on any date of determination prior to the Commitment
Termination Date, the percentage that such Lender’s Commitment bears to the aggregate Commitments of all the Lenders; or (b) on any date of determination on or after the Commitment Termination Date, the percentage that such Lender’s
Credit Exposure bears to the aggregate Credit Exposure of all the Lenders. 

					
		  		  	  
 Revolving Loan Agreement

 “Applicable Rate” means, for any day, with respect to any ABR Loan or Eurodollar
Loan, or with respect to the facility fees payable hereunder, as the case may be, the applicable rate per annum set forth below under the caption “ABR Margin”, “Eurodollar Margin” or “Facility Fee
Rate”, respectively, based upon the Leverage Ratio as of the most recent determination date: 
  

										
	 Maximum Leverage Ratio
	  	ABR Margin	 	 	Eurodollar Margin	 	 	Facility Fee Rate	 
	 Category 1
 Less than 1.50x
	  	0.000	%	 	0.400	%	 	0.100	%
				
	 Category 2
 Equal to or greater than 1.50x but less than 2.0x
	  	0.000	%	 	0.500	%	 	0.125	%
				
	 Category 3
 Equal to or greater than 2.0x but less than 2.50x
	  	0.000	%	 	0.600	%	 	0.150	%
				
	 Category 4
 Greater than or equal to 2.50x
	  	0.000	%	 	0.750	%	 	0.250	%

 For purposes of the foregoing, (i) the Leverage Ratio shall be determined as of the end of each fiscal
quarter of the Borrower’s fiscal year based upon the Borrower’s consolidated financial statements delivered pursuant to Section 5.01(a) or (b) and (ii) each change in the Applicable Rate resulting
from a change in the Leverage Ratio shall be effective during the period commencing on and including the date three Business Days after delivery to the Administrative Agent of such consolidated financial statements indicating such change and ending
on the date immediately preceding the effective date of the next such change; provided that (i) the Leverage Ratio shall be deemed to be in Category 4 (A) at any time that an Event of Default has occurred and is continuing and
(B) if the Borrower fails to deliver the consolidated financial statements required to be delivered by it pursuant to Section 5.01(a) or (b), during the period from the expiration of the time for delivery
thereof until such consolidated financial statements are delivered; and (ii) notwithstanding the foregoing, (A) from the Effective Date until the date of delivery pursuant to Section 5.01 of the Borrower’s
consolidated financial statements for the fiscal year ending December 31, 2007 (the “2007 Fiscal Year Delivery Date”), the “Applicable Rate” shall be the applicable rates per annum set forth above
in Category 1, and (b) on the 2007 Fiscal Year Delivery Date until the date three Business Days after the delivery pursuant to Section 5.01 of the Borrower’s consolidated financial statements for the fiscal quarter
ending March 31, 2008 (the “2008 First Fiscal Quarter Delivery Date”), the “Applicable Rate” shall be the applicable rates per annum set forth above in Category 2, and (c) on and after the
third Business Day following the 2008 First Fiscal Quarter Delivery Date, the “Applicable Rate” shall be determined in accordance with the chart set forth above. 
 “Approved Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or
(c) an entity or an Affiliate of an entity that administers or manages a Lender. 

					
		  	2	  	  
 Revolving Loan Agreement

 “Arranger” means Wells Fargo Bank, National Association as sole
lead arranger and sole bookrunner. 
 “Assignment and Assumption” means an assignment and assumption entered into by
a Lender and an assignee (with the consent of any party whose consent is required by Section 9.04), and accepted by the Administrative Agent, in the form of Exhibit A or any other form approved by the Administrative
Agent. 
 “Availability Period” means the period from and including the Effective Date to the Commitment Termination
Date. 
 “Board” means the Board of Governors of the Federal Reserve System of the United States of America.

 “Borrower” means Harte-Hanks, Inc., a Delaware corporation. 
 “Borrowing” means (a) all ABR Loans or (b) all Eurodollar Loans of the same Type that have the same Interest Period.
For purposes hereof, the date of a Borrowing comprising Loans that have been converted or continued shall be the effective date of the most recent conversion or continuation of such Loans. 
 “Borrowing Request” means a request by the Borrower for a Borrowing in accordance with Section 2.03.

 “Business Day” means any day that is not a Saturday, Sunday or other day on which commercial banks in Dallas,
Texas and San Francisco, California are authorized or required by law to remain closed; provided that, when used in connection with a Eurodollar Loan, the term “Business Day” shall also exclude any day on which banks
are not open for dealings in dollar deposits in the London interbank market. 
 “Capital Lease Obligations” of any
Person means the obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and
accounted for as capital leases on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. 
 “Change in Control” means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person
or group (within the meaning of the Securities Exchange Act of 1934 and the rules of the Securities and Exchange Commission thereunder as in effect on the date hereof), of shares representing more than 25% of the aggregate ordinary voting power
represented by the issued and outstanding capital stock of the Borrower; (b) occupation of a majority of the seats (other than vacant seats) on the board of directors of the Borrower by Persons who were neither (i) nominated by the board
of directors of the Borrower nor (ii) appointed by directors so nominated; or (c) the acquisition of direct or indirect Control of the Borrower by any Person or group. 
 “Change in Law” means (a) the adoption of any law, rule or regulation after the date of this Agreement, (b) any change
in any law, rule or regulation or in the interpretation or application thereof by any Governmental Authority after the date of this Agreement or (c) compliance by any Lender (or, for purposes of Section 2.12, by any lending
office of such Lender or by such Lender’s holding company, if any) with any request, guideline or directive (whether or not having the force of law) of any Governmental Authority made or issued after the date of this Agreement. 

					
		  	3	  	  
 Revolving Loan Agreement

 “Code” means the Internal Revenue Code of 1986, as amended from time to time.

 “Commitment” means, with respect to each Lender on any date of determination, the commitment of such Lender to
make Loans hereunder, as such commitment may be (a) reduced from time to time pursuant to Section 2.06, and (b) reduced or increased from time to time pursuant to assignments by or to such Lender pursuant to
Section 9.04. The initial amount of each Lender’s Commitment is set forth on Schedule I, or in the Assignment and Assumption pursuant to which such Lender shall have assumed its Commitment, as applicable. The
aggregate Commitments on the Effective Date is $50,000,000. 
 “Commitment Termination Date” means the earliest of
(i) the Business Day immediately preceding the Maturity Date and (ii) any date upon which all of the Commitments of the Lenders to make Loans have been terminated in accordance with the terms of this Agreement. 
 “Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or
policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. 
 “Credit Exposure” means, with respect to any Lender at any time, the sum of the outstanding principal amount of such
Lender’s Loans. 
 “Default” means any event or condition which constitutes an Event of Default or which upon
notice, lapse of time or both would, unless cured or waived, become an Event of Default. 
 “Disclosed Matters” means
the actions, suits and proceedings disclosed in Schedule III and the environmental matters disclosed in Schedule IV. 
 “Disposition” means any sale, assignment, transfer or other disposition of any property (whether now owned or hereafter acquired) by the Borrower or any of its Subsidiaries to any other Person
(other than the Borrower or any of its Subsidiaries) excluding (i) any sale, assignment, transfer or other disposition of any property sold or disposed of in the ordinary course of business and on ordinary business terms and (ii) any loss
or damage to, or any condemnation or taking of, any property. 
 “Dollars” or “$” refers to
lawful money of the United States of America. 
 “EBITDA” means, for any period, the sum, for the Borrower and its
Subsidiaries (determined on a consolidated basis without duplication in accordance with GAAP), of the following: (a) income (loss) from operations (calculated before Interest Expense, taxes, extraordinary and unusual items and income or loss
attributable to equity in Affiliates) for such period plus (b) depreciation, amortization and other non-cash charges (to the extent deducted in determining income (loss) from operations) for such period. Notwithstanding the foregoing, if
during any period for which EBITDA is being determined, the Borrower or any of its Subsidiaries shall have consummated any acquisition or shall have consummated any Disposition, then, for all purposes of this Agreement, EBITDA shall be determined on
a pro forma basis as if such acquisition or such Disposition had been made or consummated on the first day of such period. 
 “Effective Date” means the date on which the conditions specified in Section 4.01 are satisfied (or waived in accordance with Section 9.02). 
 “Environmental Laws” means all laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, notices or
binding agreements issued, promulgated or entered into by any 

					
		  	4	  	  
 Revolving Loan Agreement

 
Governmental Authority, relating in any way to the environment, preservation or reclamation of natural resources, the management, release or threatened
release of any Hazardous Material or to health and safety matters. 
 “Environmental Liability” means any liability,
contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower or any Subsidiary directly or indirectly resulting from or based upon (a) violation of any
Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials
into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. 
 “Equity Rights” means, with respect to any Person, any subscriptions, options, warrants, commitments, preemptive rights or
agreements of any kind (including any shareholders’ or voting trust agreements) for the issuance, sale, registration or voting of, or securities convertible into, any additional shares of capital stock of any class, or partnership or other
ownership interests of any type in, such Person. 
 “ERISA” means the Employee Retirement Income Security Act of
1974, as amended from time to time. 
 “ERISA Affiliate” means any trade or business (whether or not incorporated)
that, together with the Borrower, is treated as a single employer under Section 414(b) or (c) of the Code, or, solely for purposes of Section 302 of ERISA and Section 412 of the Code, is treated as a
single employer under Section 414 of the Code. 
 “ERISA Event” means (a) any “reportable
event”, as defined in Section 4043 of ERISA or the regulations issued thereunder with respect to a Plan (other than an event for which the 30-day notice period is waived); (b) the existence with respect to any Plan of an
“accumulated funding deficiency” (as defined in Section 412 of the Code or Section 302 of ERISA), whether or not waived; (c) the filing pursuant to Section 412(d) of the Code or
Section 303(d) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan; (d) the incurrence by the Borrower or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect
to the termination of any Plan; (e) the receipt by the Borrower or any ERISA Affiliate from the PBGC or a plan administrator of any notice relating to an intention to terminate any Plan or Plans or to appoint a trustee to administer any Plan;
(f) the incurrence by the Borrower or any of its ERISA Affiliates of any liability with respect to the withdrawal or partial withdrawal from any Plan or Multiemployer Plan; or (g) the receipt by the Borrower or any ERISA Affiliate of any
notice, or the receipt by any Multiemployer Plan from the Borrower or any ERISA Affiliate of any notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in
reorganization, within the meaning of Title IV of ERISA. 
 “Eurodollar”, when used in reference to any Loan or
Borrowing, refers to such Loan, or the Loans constituting such Borrowing, that are bearing interest at a rate determined by reference to the Adjusted LIBO Rate. 
 “Event of Default” has the meaning assigned to such term in Article VII. 
 “Exchange Act” means the United States Securities Exchange Act of 1934, as amended. 

					
		  	5	  	  
 Revolving Loan Agreement

 “Excluded Taxes” means, with respect to the Administrative Agent, any Lender or
any other recipient of any payment to be made by or on account of any obligation of the Borrower hereunder, (a) income or franchise taxes imposed on (or measured by) its net income by the United States of America, or by the jurisdiction under
the laws of which such recipient is organized or in which its principal office is located or, in the case of any Lender, in which its applicable lending office is located, (b) any branch profits taxes imposed by the United States of America or
any similar tax imposed by any other jurisdiction in which the Borrower is located and (c) in the case of a Foreign Lender (other than an assignee pursuant to a request by the Borrower under Section 2.16(b)), any withholding
tax that is imposed on amounts payable to such Foreign Lender at the time such Foreign Lender becomes a party to this Agreement (or designates a new lending office) or is attributable to such Foreign Lender’s failure or inability to comply with
Section 2.14(e), except to the extent that such Foreign Lender (or its assignor, if any) was entitled, at the time of designation of a new lending office (or assignment), to receive additional amounts from the Borrower with
respect to such withholding tax pursuant to Section 2.14(a). 
 “Federal Funds Effective Rate”
means, for any day, the weighted average (rounded upwards, if necessary, to the next 1/100 of 1%) of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published on the
next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published for any day that is a Business Day, the average (rounded upwards, if necessary, to the next 1/100 of 1%) of the quotations for such day for
such transactions received by the Administrative Agent from three Federal funds brokers of recognized standing selected by it. 
 “Financial Officer” means the chief financial officer, principal accounting officer, treasurer or controller of the Borrower. 
 “Five-Year Credit Agreement” means that certain Five-year Credit Agreement dated as of August 12, 2005, among the Borrower, certain lenders party thereto, and JPMorgan Chase Bank, N.A., as
the administrative agent thereunder (as amended, modified, restated, or supplemented from time to time). 
 “Foreign
Lender” means any Lender that is organized under the laws of a jurisdiction other than that in which the Borrower is located. For purposes of this definition, the United States of America, each State thereof and the District of Columbia
shall be deemed to constitute a single jurisdiction. 
 “Fund” means any Person (other than a natural person) that is
or will be engaged in making, purchasing, holding, or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business. 
 “GAAP” means generally accepted accounting principles in the United States of America. 
 “Governmental Authority” means the government of the United States of America, or of any other nation, or any political subdivision thereof, whether state or local, and any agency, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government. 
 “Guarantee” of or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the
guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of the guarantor,
direct or indirect, (a) to purchase or pay (or advance or supply funds for 

					
		  	6	  	  
 Revolving Loan Agreement

 
the purchase or payment of) such Indebtedness or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof,
(b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness of the payment thereof, (c) to maintain working capital, equity capital or any other financial statement condition or
liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or (d) as an account party in respect of any letter of credit or letter of guaranty issued to support such Indebtedness; provided that the term
Guarantee shall not include endorsements for collection or deposit in the ordinary course of business. 
 “Hazardous
Materials” means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos containing materials,
polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law. 
 “Hedging Agreement” means any interest rate protection agreement, foreign currency exchange agreement, commodity price protection agreement or other interest or currency exchange rate or
commodity price hedging arrangement. 
 “Indebtedness” of any Person means, without duplication, (a) all
obligations of such Person for borrowed money (or with respect to deposits or advances of any kind that have substantially the same effect as obligations for borrowed money), (b) all obligations of such Person evidenced by bonds, debentures,
notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid (excluding current accounts payable incurred in the ordinary course of business), (d) all obligations of such Person under
conditional sale or other title retention agreements relating to property acquired by such Person, (e) all obligations of such Person in respect of the deferred purchase price of property or services (excluding current accounts payable incurred
in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such
Person, whether or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all Capital Lease Obligations of such Person, (i) all obligations, contingent or otherwise, of
such Person in respect of bankers’ acceptances, and (j) in respect of the Borrower, the sum of (i) the aggregate undrawn amount of all outstanding Letters of Credit plus (ii) the aggregate unreimbursed amount of payments
made by the issuers of Letters of Credit pursuant to such Letters of Credit. The Indebtedness of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner) to the extent such
Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor. 
 “Indemnified Taxes” means Taxes other than Excluded Taxes. 
 “Interest Coverage Ratio” means, as at any date of determination thereof, the ratio of (a) EBITDA for the period of four
fiscal quarters ending on or most recently ended prior to such date to (b) Interest Expense for such period. 
 “Interest
Election Request” means a request by the Borrower to convert or continue a Borrowing in accordance with Section 2.05. 
 “Interest Expense” means, for any period, the sum, for the Borrower and its Subsidiaries (determined on a consolidated basis without duplication in accordance with GAAP), of the following:
(a) all interest in respect of Indebtedness (including the interest component of any payments in respect of Capital Lease Obligations) accrued or capitalized during such period (whether or not actually paid during such period) plus
(b) the net amount payable (or minus the net amount receivable) under Hedging 

					
		  	7	  	  
 Revolving Loan Agreement

 
Agreements relating to interest during such period (whether or not actually paid or received during such period) plus (c) all fees, commissions,
and other charges payable by the Borrower in respect of letters of credit included in the definition of “Indebtedness” hereunder. Notwithstanding the foregoing, if during any period for which Interest Expense is being determined,
the Borrower or any of its Subsidiaries shall have consummated any acquisition or Disposition, then, for all purposes of this Agreement, Interest Expense shall be determined on a pro forma basis as if such acquisition or Disposition (and any
Indebtedness incurred by the Borrower or any of its Subsidiaries in connection with such acquisition or repaid as a result of such Disposition) had been made or consummated (and such Indebtedness incurred or repaid) on the first day of such period.

 “Interest Payment Date” means (a) with respect to any ABR Loan, each Quarterly Date, and (b) with
respect to any Eurodollar Loan, the last day of each Interest Period therefor and, in the case of any Interest Period for a Eurodollar Loan of more than three months’ duration, each day prior to the last day of such Interest Period that occurs
at three-month intervals after the first day of such Interest Period. 
 “Interest Period” means for any Eurodollar
Loan, the period commencing on the date of such Eurodollar Loan and ending on the numerically corresponding day in the calendar month that is one, two, three or six months thereafter, as specified in the applicable Borrowing Request or Interest
Election Request; provided, that (i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless, such next succeeding Business Day would fall in
the next calendar month, in which case such Interest Period shall end on the next preceding Business Day, and (ii) any Interest Period that commences on the last Business Day of a calendar month (or on a day for which there is no numerically
corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period. For purposes hereof, the date of a Loan initially shall be the date on which such Loan is
made and, thereafter shall be the effective date of the most recent conversion or continuation of such Loan. 
 “Lenders” means the Persons listed on Schedule I and any other Person that shall have become a party hereto pursuant to an Assignment and Assumption (other than any such Person that ceases to be a party
hereto pursuant to an Assignment and Assumption). 
 “Letters of Credit” means, on any date of determination,
all letters of credit then issued pursuant to the Five-Year Credit Agreement. 
 “Leverage Ratio” means, as at any
date, the ratio of (a) Indebtedness of the Borrower and its Subsidiaries (determined on a consolidated basis without duplication in accordance with GAAP) on such date to (b) EBITDA for the period of four fiscal quarters ending on or most
recently ended prior to such date. 
 “LIBO Rate” means, for the Interest Period for any Eurodollar Borrowing, the
rate appearing on Page 3750 of the Telerate Service (or on any successor or substitute page of such Service, or any successor to or substitute for such Service, providing rate quotations comparable to those currently provided on such page of such
Service, as determined by the Administrative Agent from time to time for purposes of providing quotations of interest rates applicable to Dollar deposits in the London interbank market) at approximately 11:00 a.m., London time, two Business Days
prior to the commencement of such Interest Period, as the rate for the offering of Dollar deposits with a maturity comparable to such Interest Period. 

					
		  	8	  	  
 Revolving Loan Agreement

 “Lien” means, with respect to any asset, (a) any mortgage, deed of trust,
lien, pledge, hypothecation, encumbrance securing the performance of an obligation, charge or security interest in, on or of such asset (including, in the case of any account or other receivable, any sale thereof other than sales thereof in the
ordinary course of business for purposes of collection of past-due receivables) and (b) the interest of a vendor or a lessor under any conditional sale agreement, capital lease or title retention agreement (or any financing lease having
substantially the same economic effect as any of the foregoing) relating to such asset. 
 “Loan Documents” means this
Agreement and documents, instruments, and certificates delivered pursuant to or in connection with this Agreement. 
 “Loans” means the revolving loans made by the Lenders to the Borrower pursuant to this Agreement. 
 “Margin Stock” means “margin stock” within the meaning of Regulations T, U and X of the Board. 
 “Material Adverse Effect” means a material adverse effect on (a) the business, assets, properties, operations, prospects or condition, financial or otherwise, of the Borrower and its Subsidiaries taken as a
whole, (b) the ability of the Borrower to perform any of its obligations under this Agreement or any of the other Loan Documents, or (c) rights of or benefits available to the Lenders under this Agreement or any of the other Loan
Documents. 
 “Material Indebtedness” means Indebtedness (other than the Loans), or obligations in respect of one or
more Hedging Agreements, of any one or more of the Borrower and its Subsidiaries in an aggregate principal amount exceeding $20,000,000. For purposes of determining Material Indebtedness, the “principal amount” of the obligations of
any Person in respect of any Hedging Agreement at any time shall be the maximum aggregate amount (giving effect to any netting agreements) that such Person would be required to pay if such Hedging Agreement were terminated at such time. 

“Material Subsidiary” means any Subsidiary which (i) accounts for more than 5% of the total consolidated revenue of the
Borrower and its Subsidiaries or (ii) represents more than 5% of the total consolidated assets of the Borrower and its Subsidiaries. 
 “Maturity Date” means the earliest of (a) July 18, 2008, or (b) the date upon which the maturity of the Loans has been accelerated; provided, however, that, in each case, if such date is
not a Business Day, the Maturity Date shall be the preceding Business Day. 
 “Multiemployer Plan” means a
multiemployer plan as defined in Section 4001(a)(3) of ERISA. 
 “Other Taxes” means any and all present
or future stamp or documentary taxes or any other excise or property taxes, charges or similar levies arising from any payment made under any Loan Document or from the execution, delivery or enforcement of, or otherwise with respect to any Loan
Document. 
 “PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor
entity performing similar functions. 
 “Permitted Encumbrances” means: 
 (a) Liens imposed by law for Taxes that are not yet due or are being contested in compliance with Section 5.04;

					
		  	9	  	  
 Revolving Loan Agreement

 (b) carriers’, warehousemen’s, mechanics’, materialmen’s,
repairmen’s and other like Liens imposed by law, arising in the ordinary course of business and securing obligations that are not overdue by more than 30 days or are being contested in compliance with Section 5.04;

 (c) pledges and deposits made in the ordinary course of business in compliance with workers’ compensation,
unemployment insurance and other social security laws or regulations; 
 (d) cash deposits to secure the performance of bids,
trade contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; and 
 (e) judgment liens in respect of judgments that do not constitute an Event of Default under clause (k) of Article
VII 
 provided that the term “Permitted Encumbrances” shall not include any Lien securing Indebtedness. 

“Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company,
partnership, Governmental Authority or other entity. 
 “Plan” means any employee pension benefit plan (other than a
Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, and in respect of which the Borrower or any ERISA Affiliate is (or, if such plan were terminated, would
under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA. 
 “Prime Rate” means the rate of interest per annum publicly announced from time to time by Wells Fargo as its prime rate in effect at its principal office in San Francisco; each change in the Prime Rate shall be
effective from and including the date such change is publicly announced as being effective. 
 “Quarterly Dates”
means the last Business Day of the three full-calendar month period immediately following the Effective Date and the last Business Day of each three-calendar month period thereafter. 
 “Quarterly Report” has the meaning assigned to such term in Section 5.01(b). 
 “Register” has the meaning set forth in Section 9.04(c). 
 “Related Parties” means, with respect to any specified Person, such Person’s Affiliates and the respective directors,
officers, employees, agents and advisors of such Person and such Person’s Affiliates. 
 “Required Lenders”
means, at any time, Lenders having Credit Exposures and unused Commitments representing more than 50% of the sum of the aggregate amount of the Credit Exposures and unused Commitments of all the Lenders at such time. 
 “Statutory Reserve Rate” means, for any Eurodollar Borrowing (determined for the applicable Interest Period), a fraction
(expressed as a decimal), the numerator of which is the number one and the denominator of which is the number one minus the arithmetic mean, taken over each day in such Interest Period, of the aggregate of the maximum reserve percentages
(including any marginal, special, 

					
		  	10	  	  
 Revolving Loan Agreement

 
emergency or supplemental reserves) expressed as a decimal established by the Board to which the Administrative Agent is subject for eurocurrency funding
(currently referred to as “Eurocurrency liabilities” in Regulation D of the Board). Such reserve percentages shall include those imposed pursuant to such Regulation D. Eurodollar Loans shall be deemed to constitute eurocurrency
funding and to be subject to such reserve requirements without benefit of or credit for proration, exemptions or offsets that may be available from time to time to any Lender under such Regulation D or any comparable regulation. The Statutory
Reserve Rate shall be adjusted automatically on and as of the effective date of any change in any reserve percentage. 
 “Subsidiary” means, with respect to any Person (the “parent”) at any date, any corporation, limited liability company, partnership, association or other entity the accounts of which would be
consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, limited liability company,
partnership, association or other entity of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the general
partnership interests are, as of such date, owned, controlled or held. Unless otherwise specified, “Subsidiary” means a Subsidiary of the Borrower. 
 “Taxes” means any and all present or future taxes, levies, imposts, duties, deductions, charges or withholdings imposed by any
Governmental Authority. 
 “Transactions” means the execution, delivery and performance by the Borrower of this
Agreement and the other Loan Documents, the borrowing of Loans, and the use of the proceeds thereof. 
 “Type”, when
used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans constituting such Borrowing, is determined by reference to the Adjusted LIBO Rate or the Alternate Base Rate. 
 “Wells Fargo” means Wells Fargo Bank, National Association. 
 “Withdrawal Liability” means liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such
Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA. 
 SECTION 1.02. Terms
Generally. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The
words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”. The word “will” shall be construed to have the same
meaning and effect as the word “shall”. Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (b) any reference herein to any Person shall be
construed to include such Person’s successors and assigns, (c) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in
its entirety and not to any particular provision hereof, (d) all references herein to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement and
(e) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and
contract rights. 

					
		  	11	  	  
 Revolving Loan Agreement

 SECTION 1.03. Accounting Terms; GAAP. Except as otherwise expressly provided herein, all
terms of an accounting or financial nature shall be construed in accordance with GAAP, as in effect from time to time; provided that, if the Borrower notifies the Administrative Agent that the Borrower requests an amendment to any provision
hereof to eliminate the effect of any change occurring after the date hereof in GAAP or in the application thereof on the operation of such provision (or if the Administrative Agent notifies the Borrower that the Required Lenders request an
amendment to any provision hereof for such purpose), regardless of whether any such notice is given before or after such change in GAAP or in the application thereof, then such provision shall be interpreted on the basis of GAAP as in effect and
applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in accordance herewith. 
 ARTICLE II 
 THE CREDITS 
 SECTION 2.01. The Commitments. Subject to the terms and conditions set forth herein, each Lender severally agrees to make Loans to the
Borrower from time to time, on any Business Day during the Availability Period in an aggregate principal amount that will not result in (a) such Lender’s Loans exceeding such Lender’s Commitment or (b) the sum of the total Loans
exceeding the total Commitments of all the Lenders. Each Borrowing shall consist of Loans made simultaneously by the Lenders in accordance with their respective Applicable Percentages. Within the foregoing limits and subject to the terms and
conditions set forth herein, amounts borrowed and repaid or prepaid may be reborrowed. 
 SECTION 2.02. Loans and Borrowings.

 (a) Obligations of Lenders. Each Loan shall be made as part of a Borrowing consisting of Loans of the same Type made
by the Lenders ratably in accordance with their respective Commitments. The failure of any Lender to make any Loan required to be made by it shall not relieve any other Lender of its obligations hereunder; provided that the Commitments of the
Lenders are several and no Lender shall be responsible for any other Lender’s failure to make Loans as required. 
 (b)
Type of Loans. Subject to Section 2.11, each Loan shall be constituted entirely of ABR Loans or of Eurodollar Loans as the Borrower may request in accordance herewith. Each Lender at its option may make any Eurodollar Loan
by causing any domestic or foreign branch or Affiliate of such Lender to make such Loan; provided that any exercise of such option shall not affect the obligation of the Borrower to repay such Loan in accordance with the terms of this
Agreement. 
 (c) Minimum Amounts; Limitation on Number of Borrowings. Each Eurodollar Borrowing shall be in an
aggregate amount of $2,000,000 or a larger multiple of $1,000,000. Each ABR Borrowing shall be in an aggregate amount equal to $2,000,000 or a larger multiple of $1,000,000; provided that an ABR Borrowing may be in an aggregate amount that is
equal to the entire unused balance of the aggregate Commitments. Borrowings of more than one Type may be outstanding at the same time; provided that there shall not at any time be more than a total of ten (10) Eurodollar Borrowings
outstanding. Subject to the limitations set forth herein, Borrower may borrow, repay, and reborrow under each Lender’s Commitment without premium or penalty. 

					
		  	12	  	  
 Revolving Loan Agreement

 (d) Limitations on Interest Periods. Notwithstanding any other provision of this
Agreement, the Borrower shall not be entitled to request Eurodollar Borrowings (or to elect to convert to, or continue as, a Eurodollar Borrowing) prior to the Maturity Date if the Interest Period requested therefor would end after the Maturity
Date. 
 SECTION 2.03. Requests for Borrowings. 
 (a) Notice by the Borrower. To request a Borrowing, the Borrower shall notify the Administrative Agent of such request by telephone
(i) in the case of a Eurodollar Borrowing, not later than 10:00 a.m., Dallas, Texas time, three Business Days before the date of the proposed Borrowing or (ii) in the case of an ABR Borrowing, not later than 10:00 a.m., Dallas, Texas time,
one Business Day before the date of the proposed Borrowing. Each such telephonic Borrowing Request shall be irrevocable and shall be confirmed promptly by hand delivery or telecopy to the Administrative Agent of a written Borrowing Request in a form
approved by the Administrative Agent and signed by the Borrower. 
 (b) Content of Borrowing Requests. Each telephonic
and written Borrowing Request shall specify the following information in compliance with Section 2.02: 
 (i) the aggregate amount of the requested Borrowing; 
 (ii) the date of such Borrowing, which shall be a Business
Day; 
 (iii) whether such Borrowing is to be an ABR Borrowing or a Eurodollar Borrowing; 
 (iv) in the case of a Eurodollar Borrowing, the Interest Period therefor, which shall be a period contemplated by the definition of the
term “Interest Period” and permitted under Section 2.02(d); and 
 (v) the location and
number of the Borrower’s account to which funds are to be disbursed, which shall comply with the requirements of Section 2.04. 
 (c) Notice by the Administrative Agent to the Lenders. Promptly following receipt of a Borrowing Request in accordance with this Section, the Administrative Agent shall advise each Lender of the details thereof
and of the amount of such Lender’s Loan to be made as part of the requested Borrowing. 
 (d) Failure to Elect. If
no election as to the Type of a Borrowing is specified, then the requested Borrowing shall be an ABR Borrowing. If no Interest Period is specified with respect to any requested Eurodollar Borrowing, then the requested Borrowing shall be made instead
as an ABR Borrowing. 
 SECTION 2.04. Funding of Borrowings. 
 (a) Funding by Lenders. Each Lender shall make each Loan to be made by it hereunder on the proposed date thereof by wire transfer
of immediately available funds by 11:00 a.m., Dallas, Texas time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the Lenders. The Administrative Agent will make such Loans available to the
Borrower by promptly crediting the amounts so received, in like funds, to an account of the Borrower maintained with the Administrative Agent and designated by the Borrower in the applicable Borrowing Request. 

					
		  	13	  	  
 Revolving Loan Agreement

 (b) Presumption by the Administrative Agent. Unless the Administrative Agent shall
have received notice from a Lender prior to the proposed date of any Borrowing that such Lender will not make available to the Administrative Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has
made such share available on such date in accordance with paragraph (a) of this Section and may, in reliance upon such assumption, make available to the Borrower a corresponding amount. In such event, if a Lender has not in fact made its share
of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding amount with interest thereon, for each day from
and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (i) in the case of such Lender, the greater of the Federal Funds Effective Rate and a rate determined by
the Administrative Agent in accordance with banking industry rules on interbank compensation or (ii) in the case of the Borrower, the interest rate applicable to ABR Loans. If such Lender pays such amount to the Administrative Agent, then such
amount shall constitute such Lender’s Loan included in such Borrowing. 
 SECTION 2.05. Interest Elections. 
 (a) Elections by the Borrower for Borrowings. The Loans constituting each Borrowing initially shall be of the Type specified in the
applicable Borrowing Request and, in the case of a Eurodollar Borrowing, shall have the Interest Period specified in such Borrowing Request. Thereafter, the Borrower may elect to convert such Borrowing to a Borrowing of a different Type or to
continue such Borrowing as a Borrowing of the same Type and, in the case of a Eurodollar Borrowing, may elect the Interest Period therefor, all as provided in this Section. The Borrower may elect different options with respect to different portions
of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding the Loans constituting such Borrowing, and the Loans constituting each such portion shall be considered a separate Borrowing. 

(b) Notice of Elections. To make an election pursuant to this Section, the Borrower shall notify the Administrative Agent of
such election by telephone by the time that a Borrowing Request would be required under Section 2.03 if the Borrower were requesting a Borrowing of the Type resulting from such election to be made on the effective date of such
election. Each such telephonic Interest Election Request shall be irrevocable and shall be confirmed promptly by hand delivery or telecopy to the Administrative Agent of a written Interest Election Request in a form approved by the Administrative
Agent and signed by the Borrower. 
 (c) Content of Interest Election Requests. Each telephonic and written Interest
Election Request shall specify the following information in compliance with Section 2.02: 
 (i) the
Borrowing to which such Interest Election Request applies and, if different options are being elected with respect to different portions thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be
specified pursuant to clauses (iii) and (iv) of this paragraph shall be specified for each resulting Borrowing); 
 (ii) the effective date of the election made pursuant to such Interest Election Request, which shall be a Business Day; 

					
		  	14	  	  
 Revolving Loan Agreement

 (iii) whether the resulting Borrowing is to be an ABR Borrowing or a Eurodollar
Borrowing; and 
 (iv) if the resulting Borrowing is a Eurodollar Borrowing, the Interest Period therefor after giving effect
to such election, which shall be a period contemplated by the definition of the term “Interest Period” and permitted under Section 2.02(d). 
 (d) Notice by the Administrative Agent to the Lenders. Promptly following receipt of an Interest Election Request, the
Administrative Agent shall advise each Lender of the details thereof and of such Lender’s portion of each resulting Borrowing. 
 (e) Failure to Elect; Events of Default. If the Borrower fails to deliver a timely and complete Interest Election Request with respect to a Eurodollar Borrowing prior to the end of the Interest Period therefor, then, unless such
Eurodollar Borrowing is repaid as provided herein at the end of the applicable Interest Period, then such Eurodollar Borrowing shall be converted to an ABR Borrowing. Notwithstanding any contrary provision hereof, if an Event of Default has occurred
and is continuing and the Administrative Agent, at the request of the Required Lenders, so notifies the Borrower, then, so long as an Event of Default is continuing (i) no outstanding Borrowing may be converted to or continued as a Eurodollar
Borrowing, and (ii) unless repaid, each Eurodollar Borrowing shall be converted to an ABR Borrowing at the end of the Interest Period therefor. 
 SECTION 2.06. Termination and Reduction of the Commitments. 
 (a) Scheduled
Termination. The Commitments shall automatically and permanently reduce to zero at the close of business on the Commitment Termination Date. 
 (b) Voluntary Termination or Reduction. The Borrower may at any time terminate, or from time to time reduce, the Commitments; provided that each reduction of the Commitments shall be in an amount that is
$10,000,000 or a larger multiple of $5,000,000. 
 (c) Notice of Voluntary Termination or Reduction. The Borrower shall
notify the Administrative Agent of any election to terminate or reduce the Commitments under paragraph (b) of this Section at least three Business Days prior to the effective date of such termination or reduction, specifying such election and
the effective date thereof. Promptly following receipt of any notice, the Administrative Agent shall advise the Lenders of the contents thereof. Each notice delivered by the Borrower pursuant to this Section shall be irrevocable; provided
that a notice of termination of the Commitments delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by notice to the
Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. 
 (d) Effect of
Termination or Reduction. Any termination or reduction of the Commitments shall be permanent. Each reduction of the Commitments shall be made ratably among the Lenders in accordance with their respective Commitments then in effect. 

SECTION 2.07. Repayment of Loans; Evidence of Debt. 
 (a) Repayment. On the Maturity Date, the Borrower hereby unconditionally promises to pay to the Administrative Agent, for the
account of the Lenders, the then unpaid principal amount of the Loans, together with all accrued and unpaid interest and fees and other amounts owed to the Lenders or the Administrative Agent under the Loan Documents. 

					
		  	15	  	  
 Revolving Loan Agreement

 (b) Manner of Payment. Prior to any repayment of any Borrowings hereunder, the
Borrower shall select the Borrowing or Borrowings to be paid and shall notify the Administrative Agent by telephone (confirmed by telecopy) of such selection not later than 10:00 a.m., Dallas, Texas time, three Business Days before the scheduled
date of such repayment; provided that each repayment of Borrowings shall be applied to repay any outstanding ABR Borrowings before any other Borrowings. If the Borrower fails to make a timely selection of the Borrowing or Borrowings to be
repaid or prepaid, such payment shall be applied, first, to pay any outstanding ABR Borrowings; second, to other Borrowings in the order of the remaining duration of their respective Interest Periods (the Borrowing with the shortest
remaining Interest Period to be repaid first). Each payment of a Borrowing shall be applied ratably to the Loans included in such Borrowing. 
 (c) Maintenance of Records by Lenders. Each Lender shall maintain in accordance with its usual practice records evidencing the indebtedness of the Borrower to such Lender resulting from each Loan made by such
Lender, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder. 
 (d)
Maintenance of Records by the Administrative Agent. The Administrative Agent shall maintain records in which it shall record (i) the amount of each Loan made hereunder, the Type thereof and each Interest Period therefor, (ii) the
amount of any principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder and (iii) the amount of any sum received by the Administrative Agent hereunder for account of the Lenders and each
Lender’s share thereof. 
 (e) Effect of Entries. The entries made in the records maintained pursuant to paragraph
(c) or (d) of this Section shall be prima facie evidence of the existence and amounts of the obligations recorded therein; provided that the failure of any Lender or the Administrative Agent to maintain such records or any
error therein shall not in any manner affect the obligation of the Borrower to repay the Loans in accordance with the terms of this Agreement. 
 (f) Promissory Notes. Any Lender may request that Loans made by it be evidenced by a promissory note. In such event, the Borrower shall prepare, execute and deliver to such Lender a promissory note payable to
the order of such Lender (or, if requested by such Lender, to such Lender and its registered assigns) and in a form approved by the Administrative Agent. Thereafter, the Loans evidenced by such promissory note and interest thereon shall at all times
(including after assignment pursuant to Section 9.04) be represented by one or more promissory notes in such form payable to the order of the payee named therein (or, if such promissory note is a registered note, to such payee and
its registered assigns). 
 SECTION 2.08. Prepayment of Loans. 
 (a) Right to Prepay Borrowings. The Borrower shall have the right at any time and from time to time to prepay any Borrowing in
whole or in part without premium or penalty, subject to the requirements of this Section. 
 (b) Notices, Etc. The
Borrower shall notify the Administrative Agent by telephone (confirmed by telecopy) of any prepayment hereunder (i) in the case of prepayment of a Eurodollar Borrowing not later than 10:00 a.m., Dallas, Texas time, three Business Days before

					
		  	16	  	  
 Revolving Loan Agreement

 
the date of prepayment, or (ii) in the case of prepayment of an ABR Borrowing, not later than 10:00 a.m., Dallas, Texas time, one Business Day before
the date of prepayment. Each such notice shall be irrevocable and shall specify the prepayment date (which shall be a Business Day) and the principal amount of each Borrowing or portion thereof to be prepaid; provided that, if a notice of
prepayment is given in connection with a conditional notice of termination of the Commitments as contemplated by Section 2.06(c), then such notice of prepayment may be revoked if such notice of termination is revoked in accordance
with Section 2.06(c). Promptly following receipt of any such notice relating to a Borrowing, the Administrative Agent shall advise the relevant Lenders of the contents thereof. Each partial prepayment of any Borrowing shall be in
an amount that would be permitted in the case of a Borrowing of the same Type as provided in Section 2.02. Each prepayment of a Borrowing shall be applied ratably to the Loans included in the prepaid Borrowing. Prepayments shall
be accompanied by accrued interest to the extent required by Section 2.10. 
 SECTION 2.09. Fees.

 (a) Facility Fee. The Borrower agrees to pay to the Administrative Agent for account of each Lender a facility fee,
which shall accrue at the Applicable Rate for Facility Fees on the amount of the Commitment of such Lender (whether used or unused) during the period from and including the Effective Date to the Commitment Termination Date; provided
that, if such Lender continues to have any Credit Exposure after the Commitment Termination Date, then such facility fee shall continue to accrue on the amount of such Lender’s Credit Exposure from and including the Commitment
Termination Date to but excluding the date on which such Lender ceases to have any Credit Exposure. Accrued facility fees shall be payable on each Quarterly Date and on the later of the date the Commitments terminate and the date upon which the
Loans of all of the Lenders shall have been paid in full, provided that (i) any facility fees accruing after the Maturity Date shall be payable on demand, and (ii) if any principal of any Loan is not paid when due, whether at stated
maturity, upon acceleration or otherwise, the facility fee in respect of such principal shall be payable on demand. All facility fees shall be computed on the basis of a year of 360 days and shall be payable for the actual number of days elapsed
(including the first day but excluding the last day). 
 (b) Payment of Fees. All fees payable hereunder, or as
provided for in a separate letter agreement with respect to this facility, shall be paid on the dates due, in immediately available funds, to the Administrative Agent for distribution, in the case of facility fees, participation fees and fronting
fees, to the Lenders entitled thereto. Fees paid shall not be refundable under any circumstances. 
 SECTION 2.10. Interest.

 (a) ABR Loans. The Loans constituting each ABR Borrowing shall bear interest at a rate per annum equal to the
Alternate Base Rate plus the Applicable Rate. 
 (b) Eurodollar Loans. The Loans constituting each Eurodollar
Borrowing shall bear interest at a rate per annum equal to the Adjusted LIBO Rate for the Interest Period for such Borrowing plus the Applicable Rate. 
 (c) Default Interest. Notwithstanding the foregoing, if any principal of or interest on any Loan or any fee or other amount payable
by the Borrower hereunder is not paid when due, whether at stated maturity, upon acceleration or otherwise, such overdue amount shall bear interest, after as well as before judgment, at a rate per annum equal to (i) in the case of overdue

					
		  	17	  	  
 Revolving Loan Agreement

 
principal of any Loan, 2% plus the rate otherwise applicable to such Loan as provided above or (ii) in the case of any other amount, 2%
plus the rate applicable to ABR Loans as provided in paragraph (a) of this Section. 
 (d) Payment of
Interest. Accrued interest on each Loan shall be payable in arrears on each Interest Payment Date for such Loan and on the Maturity Date; provided that (i) interest accrued pursuant to paragraph (c) of this Section shall be
payable on demand, (ii) in the event of any repayment or prepayment of any Loan, accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or prepayment and (iii) in the event of any
conversion of any Eurodollar Borrowing prior to the end of the Interest Period therefor, accrued interest on such Borrowing shall be payable on the effective date of such conversion. 
 (e) Computation. All interest hereunder shall be computed on the basis of a year of 360 days, except that interest computed by
reference to the Alternate Base Rate at times when the Alternate Base Rate is based on the Prime Rate shall be computed on the basis of a year of 365 days (or 366 days in a leap year), and in each case shall be payable for the actual number of days
elapsed (including the first day but excluding the last day). The applicable Alternate Base Rate and the Adjusted LIBO Rate shall be determined by the Administrative Agent, and such determination shall be conclusive absent manifest error.

 (f) Notwithstanding anything in this Section 2.10 or in other Loan Documents to the contrary, the
interest contracted for, charged, or received pursuant to this Section 2.10 or otherwise in the Loan Documents shall not exceed the Maximum Rate (as such term is defined in Section 9.14 hereof) and is subject to
the terms of Section 9.14. 
 SECTION 2.11. Alternate Rate of Interest. If prior to the commencement of the
Interest Period for any Eurodollar Borrowing: 
 (a) the Administrative Agent determines (which determination shall be
conclusive absent manifest error) that adequate and reasonable means do not exist for ascertaining the Adjusted LIBO Rate for such Interest Period; or 
 (b) the Administrative Agent is advised by the Required Lenders that the Adjusted LIBO Rate for such Interest Period will not adequately and fairly reflect the cost to such Lenders (or Lender) of making or maintaining
their respective Loans (or its Loan) included in such Borrowing for such Interest Period; 
 then the Administrative Agent shall give notice thereof to the
Borrower and the Lenders by telephone or telecopy as promptly as practicable thereafter and, until the Administrative Agent notifies the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist, (i) any
Interest Election Request that requests the conversion of any Borrowing to, or the continuation of any Borrowing as, a Eurodollar Borrowing shall be ineffective and such Borrowing (unless prepaid) shall be continued as, or converted to, an ABR
Borrowing and (ii) if any Borrowing Request requests a Eurodollar Borrowing, such Borrowing shall be made as an ABR Borrowing. 
 SECTION 2.12. Increased Costs. 
 (a) Increased Costs Generally. If any Change in Law shall:

 (i) impose, modify or deem applicable any reserve, special deposit or similar requirement against assets of, deposits with
or for account of, or credit extended by, any Lender (except any such reserve requirement reflected in the Adjusted LIBO Rate); or 

					
		  	18	  	  
 Revolving Loan Agreement

 (ii) impose on any Lender or the London interbank market any other condition affecting
this Agreement or Eurodollar Loans made by such Lender or participation therein; 
 and the result of any of the foregoing shall be to
increase the cost to such Lenders of making or maintaining any Eurodollar Loan (or of maintaining its obligation to make any such Loan) or to increase the cost to such Lender or to reduce the amount of any sum received or receivable by such Lender
hereunder (whether of principal, interest or otherwise), then the Borrower will pay to such Lender such additional amount or amounts as will compensate such Lender for such additional costs incurred or reduction suffered. 
 (b) Capital Requirements. If any Lender determines that any Change in Law regarding capital requirements has or would have the
effect of reducing the rate of return on such Lender’s capital or on the capital of such Lender’s holding company, if any, as a consequence of this Agreement or the Loans made by such Lender to a level below that which such Lender or such
Lender’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s policies and the policies of such Lender’s holding company with respect to capital adequacy), then from time to time the
Borrower will pay to such Lender such additional amount or amounts as will compensate such Lender or such Lender’s holding company for any such reduction suffered. 
 (c) Certificates from Lenders. A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or
its holding company, as the case may be, as specified in paragraph (a) or (b) of this Section, shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on
any such certificate within 10 days after receipt thereof. 
 (d) Delay in Requests. Failure or delay on the part of
any Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender’s right to demand such compensation; provided that (i) the Borrower shall not be required to compensate a Lender pursuant to
this Section for any increased costs or reductions incurred more than six months prior to the date that such Lender notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s intention to
claim compensation therefor; and (ii) if the Change in Law giving rise to such increased costs or reductions is retroactive, then the six-month period referred to above shall be extended to include the period of retroactive effect thereof.

 SECTION 2.13. Break Funding Payments. In the event of (a) the payment of any principal of any Eurodollar Loan other
than on the last day of an Interest Period therefor (including as a result of an Event of Default), (b) the conversion of any Eurodollar Loan other than on the last day of an Interest Period therefor, (c) the failure to borrow, convert,
continue or prepay any Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice is permitted to be revocable under Section 2.08(b) and is revoked in accordance herewith), or
(d) the assignment as a result of a request by the Borrower pursuant to Section 2.16 of any Eurodollar Loan other than on the last day of an Interest Period therefor, then, in any such event, the Borrower shall compensate
each Lender for the loss, cost and expense attributable to such event. In the case of a Eurodollar Loan, the loss to any Lender attributable to any such event shall be deemed to include an amount determined by such Lender to be equal to the excess,
if any, of (i) the amount of interest that such Lender would pay for a deposit equal to 

					
		  	19	  	  
 Revolving Loan Agreement

 
the principal amount of such Loan for the period from the date of such payment, conversion, failure or assignment to the last day of the then current
Interest Period for such Loan (or, in the case of a failure to borrow, convert or continue, the duration of the Interest Period that would have resulted from such borrowing, conversion or continuation) if the interest rate payable on such deposit
were equal to the Adjusted LIBO Rate for such Interest Period, over (ii) the amount of interest that such Lender would earn on such principal amount for such period if such Lender were to invest such principal amount for such period at
the interest rate that would be bid by such Lender (or an affiliate of such Lender) for Dollar deposits from other banks in the eurodollar market at the commencement of such period. A certificate of any Lender setting forth any amount or amounts
that such Lender is entitled to receive pursuant to this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within 10 days
after receipt thereof. 
 SECTION 2.14. Taxes. 
 (a) Payments Free of Taxes. Any and all payments by or on account of any obligation of the Borrower hereunder or under any other
Loan Document shall be made free and clear of and without deduction for any Indemnified Taxes or Other Taxes; provided that if the Borrower shall be required to deduct any Indemnified Taxes or Other Taxes from such payments, then (i) the
sum payable shall be increased as necessary so that after making all required deductions (including deductions applicable to additional sums payable under this Section) the Administrative Agent or Lender (as the case may be) receives an amount equal
to the sum it would have received had no such deductions been made, (ii) the Borrower shall make such deductions and (iii) the Borrower shall pay the full amount deducted to the relevant Governmental Authority in accordance with applicable
law. 
 (b) Payment of Other Taxes by the Borrower. In addition, the Borrower shall pay any Other Taxes to the relevant
Governmental Authority in accordance with applicable law. 
 (c) Indemnification by the Borrower. The Borrower shall
indemnify the Administrative Agent and each Lender within 10 days after written demand therefor, for the full amount of any Indemnified Taxes or Other Taxes paid by the Administrative Agent or such Lender on or with respect to any payment by or on
account of any obligation of the Borrower hereunder (including Indemnified Taxes or Other Taxes imposed or asserted on or attributable to amounts payable under this Section) and any penalties, interest and reasonable expenses arising therefrom or
with respect thereto, whether or not such Indemnified Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by
a Lender or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive absent manifest error. 
 (d) Evidence of Payments. As soon as practicable after any payment of Indemnified Taxes or Other Taxes by the Borrower to a Governmental Authority, the Borrower shall deliver to the Administrative Agent the original or a certified
copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. 
 (e) Foreign Lenders. Any Foreign Lender that is entitled to an exemption from or reduction of withholding tax under the law of the
jurisdiction in which the Borrower is located, or any treaty to which such jurisdiction is a party, with respect to payments under this Agreement shall deliver to the Borrower (with a copy to the Administrative Agent), at the time or times 

					
		  	20	  	  
 Revolving Loan Agreement

 
prescribed by applicable law or reasonably requested by the Borrower, such properly completed and executed documentation prescribed by applicable law as will
permit such payments to be made without withholding or at a reduced rate. 
 SECTION 2.15. Payments Generally; Pro Rata Treatment;
Sharing of Set-offs. 
 (a) Payments by the Borrower.
The Borrower shall make each payment required to be made by it hereunder (whether of principal, interest, fees or amounts payable under Section 2.12, 2.13 or 2.14, or otherwise) prior to 11:00 a.m.,
Dallas, Texas time, on the date when due, in immediately available funds, without set-off or counterclaim. Any amounts received after such time on any date may, in the discretion of the Administrative Agent, be deemed to have been received on the
next succeeding Business Day for purposes of calculating interest thereon. All such payments shall be made to the Administrative Agent at its offices at 201 3rd Street, 8th Floor, San Francisco, California 94596, except payments pursuant to Sections 2.12, 2.13,
2.14 and 9.03, which shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for account of any other Person to the appropriate recipient promptly
following receipt thereof. If any payment hereunder shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day and, in the case of any payment accruing interest, interest thereon
shall be payable for the period of such extension. All payments hereunder shall be made in Dollars. 
 (b)
Application of Insufficient Payments. If at any time insufficient funds are received by and available to the Administrative Agent to pay fully all amounts of principal, interest and fees then due hereunder, such funds shall be applied
(i) first, to pay interest and fees then due hereunder, ratably among the parties entitled thereto in accordance with the amounts of interest and fees then due to such parties; and (ii) second, to pay principal then due hereunder, ratably
among the parties entitled thereto in accordance with the amounts of principal then due to such party. 
 (c) Pro Rata
Treatment. Except to the extent otherwise provided herein: (i) each Borrowing shall be made from the Lenders, and each termination or reduction of the amount of the Commitments under Section 2.06 shall be applied to the
respective Commitments of the Lenders, pro rata according to the amounts of their respective Commitments then in effect; (ii) each payment of facility fees under Section 2.09 shall be made for the account of the Lenders pro
rata in accordance with the amount of facility fees then due and payable to the respective Lenders; (iii) each Borrowing shall be allocated pro rata among the Lenders according to the amounts of their respective Commitments then in effect (in
the case of the making of Loans) or their respective Loans that are to be included in such Borrowing (in the case of conversions and continuations of Loans); (iv) each payment or prepayment of principal of Loans by the Borrower shall be made
for account of the Lenders pro rata in accordance with the respective Credit Exposure held by them; and (v) each payment of interest on Loans by the Borrower shall be made for account of the Lenders pro rata in accordance with the amounts of
interest on such Loans then due and payable to the respective Lenders. 
 (d) Sharing of Payments by Lenders. If any
Lender shall, by exercising any right of set-off or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of its Loans resulting in such Lender receiving payment of a greater proportion of the aggregate amount
of its Loans and accrued interest thereon then due than the proportion received by any other Lender, then the Lender receiving such greater proportion shall purchase (for cash at face value) participations in the Loans of other Lenders to the extent
necessary so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate 

					
		  	21	  	  
 Revolving Loan Agreement

 
amount of principal of and accrued interest on their respective Loans; provided that (i) if any such participations are purchased and all or any
portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest, and (ii) the provisions of this paragraph shall not be construed
to apply to any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement or any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans to any
assignee or participant, other than to the Borrower or any Subsidiary or Affiliate thereof (as to which the provisions of this paragraph shall apply). The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under
applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower rights of set-off and counterclaim with respect to such participation as fully as if such Lender were a direct
creditor of the Borrower in the amount of such participation. 
 (e) Presumptions of Payment. Unless the Administrative
Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for account of the Lenders hereunder that the Borrower will not make such payment, the Administrative Agent may assume that
the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders the amount due. In such event, if the Borrower has not in fact made such payment, then each of the Lenders
severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative
Agent, at the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. 
 (f) Certain Deductions by the Administrative Agent. If any Lender shall fail to make any payment required to be made by it pursuant
to Section 2.04(b) or 2.15(e), then the Administrative Agent may, in its discretion (notwithstanding any contrary provision hereof), apply any amounts thereafter received by the Administrative Agent for account of
such Lender to satisfy such Lender’s obligations under such Sections until all such unsatisfied obligations are fully paid. 
 SECTION 2.16. Mitigation Obligations; Replacement of Lenders. 
 (a) Designation of a Different
Lending Office. If any Lender requests compensation under Section 2.12, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for account of any Lender pursuant to
Section 2.14, then such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches
or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 2.12 or 2.14, as the case may be, in the future and
(ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any
such designation or assignment. 
 (b) Replacement of Lenders. If any Lender requests compensation under
Section 2.12, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for account of any Lender pursuant to Section 2.14, or if any Lender defaults in its
obligation to fund Loans hereunder, then the Borrower may, at its sole expense and 

					
		  	22	  	  
 Revolving Loan Agreement

 
effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject
to the restrictions contained in Section 9.04), all its interests, rights and obligations under this Agreement to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such
assignment); provided that (i) the Borrower shall have received the prior written consent of the Administrative Agent, which consent shall not unreasonably be withheld, (ii) such Lender shall have received payment of an amount equal
to the outstanding principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder, from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the
case of all other amounts) and (iii) in the case of any such assignment resulting from a claim for compensation under Section 2.12 or payments required to be made pursuant to Section 2.14, such assignment
will result in a reduction in such compensation or payments. A Lender shall not be required to make any such assignment and delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower
to require such assignment and delegation cease to apply. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 The Borrower represents and warrants to the
Lenders that: 
 SECTION 3.01. Organization; Powers. Each of the Borrower and its Subsidiaries is duly organized, validly
existing and in good standing under the laws of the jurisdiction of its organization, has all requisite power and authority to carry on its business as now conducted and, except where the failure to do so, individually or in the aggregate, could not
reasonably be expected to result in a Material Adverse Effect, is qualified to do business in, and is in good standing in, every jurisdiction where such qualification is required. 
 SECTION 3.02. Authorization; Enforceability. The Transactions are within the Borrower’s corporate powers and have been duly authorized
by all necessary corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and delivered by the Borrower and constitutes, and each of the other Loan Documents when executed and delivered will constitute,
a legal, valid and binding obligation of the Borrower, enforceable in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
 SECTION 3.03. Governmental Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of, registration or
filing with, or any other action by, any Governmental Authority, except (i) such as have been obtained or made and are in full force and effect, (ii) as may be required to be filed with the Securities & Exchange Commission after
the date hereof, (b) will not violate any applicable law or regulation or the charter, by-laws or other organizational documents of the Borrower or any of its Subsidiaries or any order of any Governmental Authority, (c) will not violate or
result in a default under any indenture, agreement or other instrument binding upon the Borrower or any of its Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such Person, and (d) will not
result in the creation or imposition of any Lien on any asset of the Borrower or any of its Subsidiaries. 

					
		  	23	  	  
 Revolving Loan Agreement

 SECTION 3.04. Financial Condition; No Material Adverse Change. 
 (a) Financial Condition. The Borrower has heretofore furnished to the Lenders (i) its consolidated balance sheet and
statements of income, stockholders’ equity and cash flows as of and for the fiscal year ended December 31, 2006, reported on by KPMG LLP, independent public accountants and (ii) its consolidated balance sheet and statements of income,
stockholders’ equity and cash flows as of and for the three-fiscal quarter period ended September 30, 2007, certified by the chief financial officer of the Borrower. Such financial statements present fairly, in all material respects, the
actual or pro forma, as the case may be, financial position and results of operations and cash flows of the Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP, subject to year-end audit adjustments and the
absence of footnotes in the case of the statements referred to in clause (ii) of the first sentence of this paragraph. None of the Borrower nor any of its Subsidiaries has on the date hereof any material contingent liabilities,
liabilities for taxes, unusual forward or long-term commitments or unrealized or anticipated losses from any unfavorable commitments, except as referred to or reflected or provided for in said balance sheet as of September 30, 2007. 

(b) No Material Adverse Change. Since September 30, 2007, there has been no material adverse change in the business,
assets, properties, operations, prospects or condition, financial or otherwise, of the Borrower and its Subsidiaries, taken as a whole. 
 SECTION 3.05. Properties. 
 (a) Property Generally. Each of the Borrower and its Subsidiaries
has good title to, or valid leasehold interests in, all its real and personal property material to their businesses, taken as a whole, subject only to Liens permitted by Section 6.01 and except for minor defects in title that do
not interfere with its ability to conduct such businesses as currently conducted or to utilize such properties for their intended purposes. 
 (b) Intellectual Property. Each of the Borrower and its Subsidiaries owns, or is licensed to use, all trademarks, tradenames, copyrights, patents and other intellectual property material to their businesses,
taken as a whole, and the use thereof by the Borrower and its Subsidiaries does not infringe upon the rights of any other Person, except for any such infringements that, individually or in the aggregate, could not reasonably be expected to result in
a Material Adverse Effect. 
 SECTION 3.06. Litigation and Environmental Matters. 
 (a) Actions, Suits and Proceedings. There are no actions, suits or proceedings by or before any arbitrator or Governmental
Authority pending against or, to the knowledge of the Borrower, threatened against or affecting the Borrower or any of its Subsidiaries (i) that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse
Effect (other than the Disclosed Matters) or (ii) that involve this Agreement or the Transactions. 
 (b)
Environmental Matters. Except for the Disclosed Matters and except with respect to any other matters that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, neither the Borrower nor any
of its Subsidiaries (i) has failed to comply with any Environmental Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (ii) has become subject to any Environmental
Liability, (iii) has received notice of any claim with respect to any Environmental Liability or (iv) knows of any basis for any Environmental Liability. 

					
		  	24	  	  
 Revolving Loan Agreement

 (c) Disclosed Matters. Since the date of this Agreement, there has been no change
in the status of the Disclosed Matters that, individually or in the aggregate, has resulted in, or could reasonably be expected to result in, a Material Adverse Effect. 
 SECTION 3.07. Compliance with Laws and Agreements. Each of the Borrower and its Subsidiaries is in compliance with all laws, regulations and orders of any Governmental Authority applicable to it or its
property and all indentures, agreements and other instruments binding upon it or its property, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. No Default
has occurred and is continuing. 
 SECTION 3.08. Investment and Holding Company Status. Neither the Borrower nor any of its
Subsidiaries is (a) an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940 or (b) a “holding company” as defined in, or subject to regulation under, the
Public Utility Holding Company Act of 1935. 
 SECTION 3.09. Taxes. Each of the Borrower and its Subsidiaries has timely filed
or caused to be filed all Tax returns and reports required to have been filed and has paid or caused to be paid all Taxes required to have been paid by it, except (a) Taxes that are being contested in good faith by appropriate proceedings and
for which such Person has set aside on its books adequate reserves or (b) to the extent that the failure to do so could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 3.10. ERISA. No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA
Events for which liability is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect. 
 SECTION 3.11. Disclosure. The Borrower has disclosed to the Lenders all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that,
individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. None of the reports, financial statements, certificates or other information furnished by or on behalf of the Borrower to the Administrative Agent
or any Lender in connection with the negotiation of this Agreement or delivered hereunder (as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any material fact necessary to
make the statements therein, in the light of the circumstances under which they were made, not misleading. 
 SECTION 3.12. Use of
Credit. The proceeds of the Loans will be used (a) to pay the fees and expenses incurred by the Borrower in connection with the Transactions, and (b) for general corporate purposes of the Borrower, including, without limitation,
acquisitions and repurchases of shares of its stock. Neither the Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose, whether immediate, incidental
or ultimate, of buying or carrying Margin Stock, and after applying the proceeds of any extension of credit hereunder, not more than 25% of the fair market value of the assets of the Borrower and its Subsidiaries consists of Margin Stock.

 SECTION 3.13. Certain Agreements and Liens. 
 (a) Certain Agreements. Part A of Schedule II is a complete and correct list of each credit agreement,
loan agreement, indenture, purchase agreement, guarantee, letter of credit or other arrangement providing for or otherwise relating to any Indebtedness or any extension of credit (or commitment for any extension of credit) to, or guarantee by, the
Borrower or any of its Subsidiaries outstanding on the date hereof the aggregate principal or face amount of each of 

					
		  	25	  	  
 Revolving Loan Agreement

 
which equals or exceeds (or may equal or exceed) $10,000,000, and the aggregate principal or face amount outstanding or that may become outstanding under
each such arrangement is correctly described in Part A of Schedule II. 
 (b) Liens.
Part B of Schedule II is a complete and correct list of each Lien securing Indebtedness of any Person outstanding on the date hereof the aggregate principal or face amount of which equals or exceeds (or may equal or
exceed) $10,000,000 and covering any property of the Borrower or any of its Subsidiaries, and the aggregate Indebtedness secured (or that may be secured) by each such Lien and the property covered by each such Lien is correctly described in
Part B of Schedule II. 
 SECTION 3.14. Subsidiaries. Set forth in Schedule V is a
complete and correct list of all of the Subsidiaries of the Borrower as of the date hereof, together with, for each such Subsidiary, (i) the jurisdiction of organization of such Subsidiary, (ii) each Person holding ownership interests in
such Subsidiary and (iii) the nature of the ownership interests held by each such Person and the percentage of ownership of such Subsidiary represented by such ownership interests. Except as disclosed in Schedule V, on the date
hereof, (x) each of the Borrower and its Subsidiaries owns, free and clear of Liens, and has the unencumbered right to vote, all outstanding ownership interests in each Person shown to be held by it in Schedule V, (y) all of
the issued and outstanding capital stock of each such Person organized as a corporation is validly issued, fully paid and nonassessable and (z) there are no outstanding Equity Rights with respect to such Person. 
 SECTION 3.15. Deferred Compensation and Incentive Plans. The Borrower has heretofore delivered to the Lenders complete and correct copies
of its Deferred Compensation Plan, 2005 Omnibus Incentive Plan and 1998 Director Stock Plan, each as in effect on the date hereof. 
 ARTICLE IV 
 CONDITIONS 
 SECTION 4.01. Effective Date. The obligations of the Lenders to make Loans hereunder shall not become effective until the date on which the Administrative Agent shall have received each of the following
documents, each of which shall be satisfactory to the Administrative Agent (and to the extent specified below, to each Lender) in form and substance (or such condition shall have been waived in accordance with Section 9.02):

 (a) Executed Counterparts. From each party hereto either (i) a counterpart of this Agreement signed on behalf
of such party or (ii) written evidence satisfactory to the Administrative Agent (which may include telecopy transmission of a signed signature page to this Agreement) that such party has signed a counterpart of this Agreement. 
 (b) Opinion of Counsel to the Borrower. A favorable written opinion (addressed to the Administrative Agent and the Lenders and
dated the Effective Date) of Cox Smith Mathews Incorporated, counsel for the Borrower, substantially in the form of Exhibit B, and covering such other matters relating to the Borrower, this Agreement or the Transactions as the Required
Lenders shall reasonably request (and the Borrower hereby instructs such counsel to deliver such opinion to the Lenders and the Administrative Agent). 
 (c) Corporate Documents. Such documents and certificates as the Administrative Agent or its counsel may reasonably request relating to the organization, existence and good standing of the Borrower, the
authorization of the Transactions and any other legal matters relating to the Borrower, this Agreement or the Transactions, all in form and substance satisfactory to the Administrative Agent and its counsel. 

					
		  	26	  	  
 Revolving Loan Agreement

 (d) Officer’s Certificate. A certificate, dated the Effective Date and signed
by the President, a Vice President or a Financial Officer of the Borrower, confirming (i) compliance with the conditions set forth in the lettered clauses of the first sentence of Section 4.02, (ii) that the Leverage
Ratio does not exceed 3.00 to 1 and (iii) that the Interest Coverage Ratio is not less than 2.75 to 1. 
 (e) Fee
Letter. A fee letter dated as of the Effective Date and signed by Borrower and Wells Fargo in a form acceptable to the Administrative Agent. 
 (f) Other Documents. Such other documents as the Administrative Agent or any Lender or special counsel to Wells Fargo may reasonably request. 
 The obligation of any Lender to make its initial extension of credit hereunder is also subject to the payment by the Borrower of such fees as the
Borrower shall have agreed to pay to any Lender or the Administrative Agent in connection herewith, including the reasonable fees and expenses of Haynes and Boone, LLP, special counsel to Wells Fargo, in connection with the negotiation, preparation,
execution and delivery of this Agreement and the extensions of credit hereunder (to the extent that statements for such fees and expenses have been delivered to the Borrower). 
 The Administrative Agent shall notify the Borrower and the Lenders of the Effective Date, and such notice shall be conclusive and binding.
Notwithstanding the foregoing, the obligations of the Lenders to make Loans hereunder shall not become effective unless each of the foregoing conditions is satisfied (or waived pursuant to Section 9.02) on or prior to 2:00 p.m.,
Dallas, Texas time, on July 31, 2008 (and, in the event such conditions are not so satisfied or waived, the Commitments shall terminate at such time). 
 SECTION 4.02. Each Credit Event. The obligation of each Lender to make a Loan on the occasion of any Borrowing is subject to the satisfaction of the following conditions: 
 (a) the representations and warranties of the Borrower set forth in this Agreement shall be true and correct on and as of the date of such
Borrowing (unless such representation and warranty is made as of a specific date, in which case, such representation and warranty shall be true and correct as of such date); and 
 (b) at the time of and immediately after giving effect to such Borrowing, no Default shall have occurred and be continuing. 
 Each Borrowing shall be deemed to constitute a representation and warranty by the Borrower on the date thereof as to the matters specified in the preceding sentence.

 ARTICLE V 
 AFFIRMATIVE COVENANTS 
 Until the Commitments have expired or been terminated and the principal of and interest on each Loan
and all fees payable hereunder shall have been paid in full the Borrower covenants and agrees with the Lenders that: 

					
		  	27	  	  
 Revolving Loan Agreement

 SECTION 5.01. Financial Statements and Other Information. The Borrower will furnish to the
Administrative Agent and each Lender: 
 (a) promptly, but in any event no later than 90 days after the end of each fiscal
year of the Borrower, the audited consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows of the Borrower and its Subsidiaries as of the end of and for such year, setting forth in each case in
comparative form the figures for the previous fiscal year, prepared in accordance with GAAP consistently applied (the “Annual Report”), all reported on by KPMG LLP or other independent public accountants of recognized
national standing (without a “going concern” or like qualification or exception and without any qualification or exception as to the scope of such audit) to the effect that such consolidated financial statements present fairly in
all material respects the financial condition and results of operations of the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP consistently applied; 
 (b) promptly, but in any event no later than 45 days after the end of each of the first three fiscal quarters of each fiscal year of the
Borrower, the consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows of the Borrower and its Subsidiaries as of the end of and for such fiscal quarter and the then elapsed portion of the fiscal
year, setting forth in each case in comparative form the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous fiscal year (the “Quarterly Report”), all
certified by one of its Financial Officers as presenting fairly in all material respects the financial condition and results of operations of the Borrower and its Subsidiaries on a consolidated basis in accordance with GAAP consistently applied,
subject to normal year-end audit adjustments and the absence of footnotes; 
 (c) concurrently with any delivery of financial
statements under clause (a) or (b) of this Section, a certificate of the Chief Executive Officer and Chief Financial Officer of the Borrower (i) certifying as to whether a Default has occurred and, if a
Default has occurred, specifying the details thereof and any action taken or proposed to be taken with respect thereto, (ii) setting forth reasonably detailed calculations demonstrating compliance with Section 6.06 and
(iii) stating whether any change in GAAP or in the application thereof has occurred since the date of the audited financial statements referred to in Section 3.04 and, if any such change has occurred, specifying the effect of
such change on the financial statements accompanying such certificate; 
 (d) concurrently with any delivery of financial
statements under clause (a) of this Section, a certificate of the accounting firm that reported on such financial statements stating whether they obtained knowledge during the course of their examination of such financial
statements of any Default (which certificate may be limited to the extent required by accounting rules or guidelines); 
 (e)
promptly after the same become publicly available, copies of all periodic and other reports, proxy statements and other materials filed by the Borrower or any of its Subsidiaries with the Securities and Exchange Commission, or any Governmental
Authority succeeding to any or all of the functions of said Commission, or with any national securities exchange, or distributed by the Borrower to its shareholders generally, as the case may be; and 
 (f) promptly following any request therefor, such other information regarding the operations, business affairs and financial condition of
the Borrower or any of its Subsidiaries, or compliance with the terms of this Agreement and the other Loan Documents, as the Administrative Agent or any Lender may reasonably request. 

					
		  	28	  	  
 Revolving Loan Agreement

 SECTION 5.02. Notices of Material Events. The Borrower will furnish to the Administrative
Agent and each Lender prompt written notice of the following: 
 (a) the occurrence of any Default; 
 (b) the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or
affecting the Borrower or any of its Affiliates that could reasonably be expected to result in a Material Adverse Effect; 
 (c) the occurrence of any ERISA Event that, alone or together with any other ERISA Events that have occurred, could reasonably be expected to result in a Material Adverse Effect; 
 (d) the assertion of any environmental matter by any Person against, or with respect to the activities of, the Borrower or any of its
Subsidiaries and any alleged violation of or non-compliance with any Environmental Laws or any permits, licenses or authorizations, other than any environmental matter or alleged violation that (either individually or in the aggregate) could not
reasonably be expected to have a Material Adverse Effect; and 
 (e) any other development that results in, or could
reasonably be expected to result in, a Material Adverse Effect. 
 Each notice delivered under this Section shall be accompanied by a statement of a
Financial Officer or other executive officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto. 
 SECTION 5.03. Existence; Conduct of Business. The Borrower will, and will cause each of its Subsidiaries to, do or cause to be done all
things necessary to preserve, renew and keep in full force and effect its legal existence and the rights, licenses, permits, privileges and franchises material to the conduct of its business; provided that the foregoing shall not prohibit any
merger, consolidation, liquidation or dissolution permitted under Section 6.02. 
 SECTION 5.04. Payment of
Obligations. The Borrower will, and will cause each of its Subsidiaries to, pay its obligations, including Tax liabilities, that, if not paid, could result in a Material Adverse Effect before the same shall become delinquent or in default,
except where (a) the validity or amount thereof is being contested in good faith by appropriate proceedings, (b) the Borrower or such Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP and
(c) the failure to make payment pending such contest could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 5.05. Maintenance of Properties; Insurance. The Borrower will, and will cause each of its Subsidiaries to, (a) keep and maintain all property material to the conduct of its business in good working order and
condition, ordinary wear and tear excepted, and (b) maintain, with financially sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar
businesses operating in the same or similar locations. 
 SECTION 5.06. Books and Records; Inspection Rights. The Borrower
will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities. The Borrower will, and will cause
each of its Subsidiaries to, permit any representatives designated by the Administrative Agent or any Lender, upon reasonable prior notice, to visit and inspect its properties, to 

					
		  	29	  	  
 Revolving Loan Agreement

 
examine and make extracts from its books and records, and to discuss its affairs, finances and condition with its officers and independent accountants, all
at such reasonable times and as often as reasonably requested. 
 SECTION 5.07. Compliance with Laws. The Borrower will, and
will cause each of its Subsidiaries to, comply with all laws, rules, regulations and orders of any Governmental Authority, including, but not limited to, Environmental Laws applicable to it or its property, except where the failure to do so,
individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. 
 ARTICLE VI 
 NEGATIVE COVENANTS 
 Until the
Commitments have expired or terminated and the principal of and interest on each Loan and all fees payable hereunder shall have been paid in full the Borrower covenants and agrees with the Lenders that: 
 SECTION 6.01. Liens. The Borrower will not, nor will it permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien
on any property or asset now owned or hereafter acquired by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect of any such income or revenues, except: 
 (a) Permitted Encumbrances; 
 (b) any Lien on any property or asset of the Borrower or any of its Subsidiaries existing on the date hereof and set forth in Part B of Schedule II (or, to the extent not meeting the
minimum thresholds for required listing on Schedule II pursuant to Section 3.13 and not otherwise listed in said Schedule II, (in a footnote or otherwise) in an aggregate amount not exceeding
$10,000,000); provided that (i) no such Lien shall extend to any other property or asset of the Borrower or any of its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and
extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof; 
 (c) any Lien
existing on any property or asset prior to the acquisition thereof by the Borrower or any Subsidiary or existing on any property or asset of any Person that becomes a Subsidiary after the date hereof prior to the time such Person becomes a
Subsidiary; provided that (i) such Lien is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be, (ii) such Lien shall not apply to any other property or
assets of the Borrower or any Subsidiary and (iii) such Lien shall secure only those obligations which it secures on the date of such acquisition or the date such Person becomes a Subsidiary, as the case may be and extensions, renewals and
replacements thereof that do not increase the outstanding principal amount thereof; 
 (d) Liens on assets acquired,
constructed or improved by the Borrower or any Subsidiary (including Liens created pursuant to Capital Lease Obligations); provided that (i) such security interests and the Indebtedness secured thereby are incurred prior to or within 365
days after such acquisition or the completion of such construction or improvement, (ii) the Indebtedness secured thereby does not exceed the cost of acquiring, constructing or improving such assets, (iii) such security interests shall not
apply to any other property or assets of the Borrower or any Subsidiary and (iv) the aggregate principal amount of Indebtedness secured by all such security interests under this paragraph (d) shall not exceed $50,000,000; 

					
		  	30	  	  
 Revolving Loan Agreement

 (e) set-off rights arising with respect to intercompany claims between the Borrower and
one or more of its Subsidiaries against the Borrower and one or more other Subsidiaries; 
 (f) With respect to letters of
credit issued for the account of the Borrower or its Subsidiaries pursuant to the Five-Year Credit Agreement, any cash collateral or defeasance account created with respect to any such letter of credit in accordance with Sections 2.06(j) and
(k) of the Five-Year Credit Agreement; 
 (g) normal and customary set-off rights and bankers’ liens with
respect to deposit accounts; and 
 (h) Liens not otherwise permitted by the foregoing clauses of this Section 6.01
securing Indebtedness not in excess of $1,000,000 at any time outstanding. 
 SECTION 6.02. Fundamental Changes.

 (a) Mergers, Consolidations, Disposal of Assets, Etc. The Borrower will not, nor will it permit any of its
Subsidiaries to, merge into or consolidate with any other Person, or permit any other Person to merge into or consolidate with it, or sell, transfer, lease or otherwise dispose of (in one transaction or in a series of transactions) any of its
assets, or any of the stock of any of its Subsidiaries (in each case, whether now owned or hereafter acquired), if the effect of any such sale of assets or stock or merger or consolidation would be to sell, transfer, lease or otherwise dispose of
all or substantially all of the assets of the Borrower and its Subsidiaries (taken as a whole) or liquidate or dissolve, except that, if at the time thereof and immediately after giving effect thereto no Default shall have occurred and be
continuing; 
 (i) any Person may merge into or consolidate with the Borrower in a transaction in which the Borrower is the
surviving corporation; 
 (ii) any Person may merge into or consolidate with any Subsidiary in a transaction in which the
surviving entity is a Subsidiary; provided that if any such merger shall be between a Subsidiary and a wholly owned Subsidiary, then the wholly owned Subsidiary shall be the continuing or surviving corporation; 
 (iii) the Borrower may merge into or consolidate with any other Person in a transaction in which such Person is the surviving entity so
long as (x) such Person assumes all of the obligations of the Borrower under this Agreement by an instrument in form and substance reasonably satisfactory to the Administrative Agent and (y) such Person delivers such proof of corporate
action, incumbency of officers, opinions of counsel and other documents as is consistent with those delivered by the Borrower pursuant to Section 4.01 on the Effective Date or as the Administrative Agent shall have reasonably
requested; 
 (iv) any Subsidiary may sell, transfer, lease or otherwise dispose of its assets to the Borrower or to another
Subsidiary; and 
 (v) any Subsidiary may liquidate or dissolve if the Borrower determines in good faith that such liquidation
or dissolution is in the best interests of the Borrower and is not materially disadvantageous to the Lenders. 

					
		  	31	  	  
 Revolving Loan Agreement

 (b) Lines of Business. The Borrower will not, nor will it permit any of its
Subsidiaries to, engage to any material extent in any business other than businesses of the type conducted by the Borrower and its Subsidiaries on the date of execution of this Agreement and businesses reasonably related thereto. 
 SECTION 6.03. Sale and Leasebacks. The Borrower will not, and will not permit any of its Subsidiaries to, directly or indirectly, become or
thereafter remain liable as lessee or as guarantor or other surety with respect to the lessee’s obligations under any lease, whether an operating lease or a capital lease, of any property (whether real or personal or mixed) whether now owned or
hereafter acquired, (a) which the Borrower or any of its Subsidiaries has sold or transferred or is to sell or transfer to any other Person or (b) which the Borrower or any such Subsidiary intends to use for substantially the same purpose
as any other property which has been or is to be sold or transferred by the Borrower or any such Subsidiary to any Person in connection with such lease, if in the case of clause (a) or (b) above, such sale and
such lease are part of the same transaction or a series of related transactions or are with the same other Person; provided that the Borrower or any Subsidiary may enter into any such transaction so long as the sale price of all such
transactions does not exceed $20,000,000 in the aggregate during the term of this Agreement. 
 SECTION 6.04. Transactions with
Affiliates. The Borrower will not, and will not permit any of its Subsidiaries to, sell, lease or otherwise transfer any property or assets to, or purchase, lease or otherwise acquire any property or assets from, or otherwise engage in any
other transactions with, any of its Affiliates, except 
 (a) transactions in the ordinary course of business at prices and on
terms and conditions not less favorable to the Borrower or such Subsidiary than could be obtained on an arm’s-length basis from unrelated third parties, 
 (b) transactions between or among the Borrower and its Subsidiaries not involving any other Affiliate, 
 (c) loans to employees of the Borrower or any Subsidiary for relocation expenses or other purposes; provided that the aggregate
outstanding principal amount of the loans permitted under this clause (c) shall not exceed $3,000,000 at any one time, 
 (d) customary obligations to directors and officers of the Borrower and its Subsidiaries in respect of indemnification and reimbursement of expenses, 
 (e) the payment of customary fees (in the form of cash, stock options or stock) to directors of the Borrower, 
 (f) the payment of compensation to officers of the Borrower approved by the Board of Directors of the Borrower, and the payment of
deferred compensation to officers of the Borrower pursuant to the Harte-Hanks, Inc. Deferred Compensation Plan (including any amendments, modifications or replacements thereof; provided that such amendment, modification or replacement does not
substantially change the character of such deferred compensation program), 
 (g) the payment of bonuses to officers and
directors of the Borrower approved by the Board of Directors of the Borrower, 

					
		  	32	  	  
 Revolving Loan Agreement

 (h) the issuance of stock of the Borrower and of options to purchase stock of the
Borrower pursuant to the Harte-Hanks 2005 Omnibus Incentive Plan (including any amendments, modifications or replacements thereof; provided that such amendment, modification or replacement does not substantially change the character of such stock
option program), and 
 (i) the purchase of stock of the Borrower and of options to purchase stock of the Borrower pursuant to
the Borrower’s stock repurchase program that was publicly announced in January 1997, as amended from time to time. 
 SECTION 6.05.
Subsidiary Indebtedness. The Borrower will not permit the aggregate principal amount of Indebtedness of its Subsidiaries (excluding any Indebtedness of a Subsidiary owed to the Borrower or another Subsidiary, but including any Guarantee
by a Subsidiary of Indebtedness of the Borrower) at any time to exceed $20,000,000. 
 SECTION 6.06. Certain Financial
Covenants. 
 (a) Leverage Ratio. The Borrower will not permit the Leverage Ratio to exceed 3.00 to 1 at any
time during the term of this Agreement. 
 (b) Interest Coverage Ratio. The Borrower will not permit the Interest
Coverage Ratio to be less than 2.75 to 1 at any time during the term of this Agreement. 
 ARTICLE VII 
 EVENTS OF DEFAULT 
 If any of the
following events (“Events of Default”) shall occur: 
 (a) the Borrower shall fail to pay any
principal of any Loan when and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or otherwise; 
 (b) the Borrower shall fail to pay any interest on any Loan, any facility fee payable under this Agreement or any other Loan Document,
when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three or more Business Days; or the Borrower shall fail to pay any other amount (other than an amount referred to in clause
(a) of this Article) payable under this Agreement or any other Loan Document, when and as the same shall become due and payable, and such failure shall continue unremedied for a period of thirty or more days; 
 (c) any representation or warranty made or deemed made by or on behalf of the Borrower or any of its Subsidiaries in or in connection with
this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document
or any amendment or modification hereof or thereof, shall prove to have been incorrect in any material respect when made or deemed made; 
 (d) the Borrower shall fail to observe or perform any covenant, condition or agreement contained in Section 5.02(a) or 5.03 (with respect to the Borrower’s existence) or in
Article VI; 

					
		  	33	  	  
 Revolving Loan Agreement

 (e) the Borrower shall fail to observe or perform any covenant, condition or agreement
contained in this Agreement or any other Loan Document (other than those specified in clause (a), (b) or (d) of this Article) and such failure shall continue unremedied for a period of 30 or more
days after notice thereof from the Administrative Agent to the Borrower; 
 (f) the Borrower or any of its Material
Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect of any Material Indebtedness, when and as the same shall become due and payable (whether at stated maturity or on acceleration);

 (g) any event or condition occurs that results in any Material Indebtedness becoming due prior to its scheduled maturity or
that enables or permits (with or without the giving of notice, but without any further lapse of time) the holder or holders of any Material Indebtedness or any trustee or agent on its or their behalf to cause any Material Indebtedness to become due,
or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this clause (g) shall not apply to (i) secured Indebtedness that becomes due as a result of the
voluntary sale or transfer of the property or assets securing such Indebtedness or (ii) the voluntary prepayment of any Indebtedness that is not then otherwise due or required to be prepaid pursuant to its terms; 
 (h) an involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or
other relief in respect of the Borrower or any of its Material Subsidiaries or its debts, or of a substantial part of its assets, under any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or
(ii) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for the Borrower or any of its Material Subsidiaries or for a substantial part of its assets, and, in any such case, such proceeding or
petition shall continue undismissed for a period of 60 or more days or an order or decree approving or ordering any of the foregoing shall be entered; 
 (i) the Borrower or any of its Material Subsidiaries shall (i) voluntarily commence any proceeding or file any petition seeking liquidation, reorganization or other relief under any Federal, state or foreign
bankruptcy, insolvency, receivership or similar law now or hereafter in effect, (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or petition described in clause (h) of
this Article, (iii) apply for or consent to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for the Borrower or any of its Material Subsidiaries or for a substantial part of its assets,
(iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors or (vi) take any action for the purpose of effecting any of the
foregoing; 
 (j) the Borrower or any of its Material Subsidiaries shall become unable, admit in writing its inability or fail
generally to pay its debts as they become due; 
 (k) one or more judgments for the payment of money in an aggregate amount in
excess of $20,000,000 shall be rendered against the Borrower or any of its Material Subsidiaries or any combination thereof and the same shall remain undischarged for a period of 30 consecutive days during which execution shall not be effectively
stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of the Borrower or any of its Material Subsidiaries to enforce any such judgment; 

					
		  	34	  	  
 Revolving Loan Agreement

 (l) an ERISA Event shall have occurred that, in the opinion of the Required Lenders, when
taken together with all other ERISA Events that have occurred, could reasonably be expected to result in a Material Adverse Effect; 
 (m) there shall have been asserted against the Borrower or any of its Subsidiaries any claims or liabilities, whether accrued, absolute or contingent, based on or arising from the generation, storage, transport, handling or disposal of
Hazardous Materials by the Borrower or any of its Subsidiaries that, in the judgment of the Required Lenders, are reasonably likely to be determined adversely to the Borrower or any of its Subsidiaries, and the amount thereof (either individually or
in the aggregate) is reasonably likely to have a Material Adverse Effect (insofar as such amount is payable by the Borrower or any of its Subsidiaries but after deducting any portion thereof that is reasonably expected to be paid by other
creditworthy Persons jointly and severally liable therefor); or 
 (n) a Change in Control shall occur. 
 then, and in every such event (other than an event with respect to the Borrower described in clause (h) or (i) of this Article),
and at any time thereafter during the continuance of such event, the Administrative Agent may, and at the request of the Required Lenders shall, by notice to the Borrower, take either or both of the following actions, at the same or different times:
(i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be due and
payable may thereafter be declared to be due and payable), and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees and other obligations of the Borrower accrued hereunder, shall
become due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower; and in case of any event with respect to the Borrower described in clause (h) or
(i) of this Article, the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon and all fees and other obligations of the Borrower accrued hereunder, shall
automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower. 
 ARTICLE VIII 
 THE ADMINISTRATIVE AGENT 
 Each of the Lenders hereby irrevocably appoints the Administrative Agent as its agent hereunder and under the other Loan Documents and authorizes the
Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. 

The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may
exercise the same as though it were not the Administrative Agent, and such Person and its Affiliates may accept deposits from, lend money to and generally engage in any kind of business with the Borrower or any Subsidiary or other Affiliate thereof
as if it were not the Administrative Agent hereunder. 
 The Administrative Agent shall not have any duties or obligations except those
expressly set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, (a) the Administrative Agent shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has
occurred and is continuing, (b) the Administrative Agent shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers 

					
		  	35	  	  
 Revolving Loan Agreement

 
expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise in writing by the Required Lenders, and
(c) except as expressly set forth herein and in the other Loan Documents, the Administrative Agent shall not have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its
Subsidiaries that is communicated to or obtained by the bank serving as Administrative Agent or any of its Affiliates in any capacity. The Administrative Agent shall not be liable for any action taken or not taken by it with the consent or at the
request of the Required Lenders or in the absence of its own gross negligence or willful misconduct. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until written notice thereof is given to the Administrative
Agent by the Borrower or a Lender, and the Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other
Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or under any other Loan Document or in connection herewith or therewith, (iii) the performance or observance of any of the covenants,
agreements or other terms or conditions set forth herein or in any other Loan Document, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document,
or (v) the satisfaction of any condition set forth in Article IV or elsewhere herein or therein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent. 
 The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent,
statement, instrument, document or other writing believed by it to be genuine and to have been signed or sent by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to be
made by the proper Person, and shall not incur any liability for relying thereon. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not
be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. 
 The
Administrative Agent may perform any and all its duties and exercise its rights and powers by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all its
duties and exercise its rights and powers through their respective Related Parties. The exculpatory provisions of the preceding paragraphs shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such
sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. 
 The Administrative Agent may resign at any time by notifying the Lenders and the Borrower. Upon any such resignation, the Required Lenders shall have the
right, in consultation with the Borrower, to appoint a successor. If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of
its resignation, then the retiring Administrative Agent’s resignation shall nonetheless become effective and (1) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and (2) the Required
Lenders shall perform the duties of the Administrative Agent (and all payments and communications provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender directly) until such time as the Required
Lenders appoint a successor agent as provided for above in this paragraph. Upon the acceptance of its appointment as Administrative Agent hereunder by a successor, such successor shall succeed to and become vested with all the rights, powers,
privileges and duties of the retiring (or retired) Administrative Agent and the retiring Administrative Agent shall be discharged from its duties and obligations hereunder (if not already discharged therefrom as provided above in this paragraph).
The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise 

					
		  	36	  	  
 Revolving Loan Agreement

 
agreed between the Borrower and such successor. After the Administrative Agent’s resignation hereunder, the provisions of this Article and
Section 9.03 shall continue in effect for the benefit of such retiring Administrative Agent, its sub agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while it was
acting as Administrative Agent. 
 Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or
any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon
the Administrative Agent or any other Lender and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any
related agreement or any document furnished hereunder or thereunder. 
 Except as otherwise provided in Section 9.02(b)
with respect to this Agreement, the Administrative Agent may, with the prior consent of the Required Lenders (but not otherwise), consent to any modification, supplement or waiver under any of the Loan Documents. 
 Anything herein to the contrary notwithstanding, none of the Bookrunner, Arranger, or agents (if any) listed on the cover page hereof shall have any
powers, duties, or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent or a Lender hereunder. 
 ARTICLE IX 
 MISCELLANEOUS 
 SECTION 9.01. Notices. 
 (a) Notices Generally. Except in the case of notices and other communications expressly permitted to be given by telephone (and subject to paragraph (b) of this Section), all notices and other communications provided for herein
shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by telecopy, as follows: 
  

	 	(i)	if to the Borrower, to: 

    Harte-Hanks, Inc. 
    200 Concord Plaza Drive, Suite 800 
    San Antonio, Texas 78216 
    Attention: Douglas Shepard, Executive Vice President and Chief Financial Officer 
    Telephone No. (210) 829-9120 
    Telecopy No. (210) 829-9403 
  

	 	(ii)	if to the Administrative Agent, to: 

  

	 	(A)	        with respect to Borrowing Requests, Interest Election Requests, and payments, to: 

 Wells Fargo Bank, National Association, as Agent 
 201 3rd Street, 8th Floor 
 San Francisco, California 94596 
 Attention: Debby Moore, Operations Administrator 
 Telephone No. (415) 477-5379 

Telecopy No. (415) 512-9408 or (415) 546-6353 

					
		  	37	  	  
 Revolving Loan Agreement

	 	(B)	        with respect to all other matters, to: 

 Wells Fargo Bank, National Association, as Agent 
 1445 Ross Avenue, Suite 2320 
 Dallas, Texas 75202 
 Attention: Greg D. Campbell, Vice President, 
 US Corporate Banking 
 Telephone No. (214) 661-1202 
 Telecopy No. (214) 969-0371 
 with copy to: 
 Haynes and Boone, LLP 
 901 Main Street, Suite 3100 
 Dallas, Texas 75202-3789 
 Attention: Karen S. Nelson, Esq. 
 Telephone No. (214) 651-5648 
 Telecopy No. (214) 200-0673 
 (iii) if to any other Lender, to it at its address (or telecopy number) set forth in its Administrative Questionnaire. 
 (b) Electronic Communications. Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communications (including email and Internet or intranet websites) pursuant
to procedures approved by the Administrative Agent; provided that the foregoing shall not apply to notices pursuant to Article II unless otherwise agreed by the Administrative Agent and the applicable Lender. The Administrative Agent
or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that approval of such procedures may be limited to particular
notices or communications. 
 (c) Change of Address, Etc. Any party hereto may change its address or telecopy number
for notices and other communications hereunder by notice to the other parties hereto (or, in the case of any such change by a Lender, by notice to the Borrower and the Administrative Agent). All notices and other communications given to any party
hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of receipt. 
 SECTION 9.02.
Waivers; Amendments. 
 (a) No Deemed Waivers; Remedies Cumulative. No failure or delay by the
Administrative Agent or any Lender in exercising any right or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a
right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Administrative Agent and the Lenders hereunder are cumulative and are not exclusive of any rights or remedies
that they would otherwise have. No waiver of any provision of this Agreement or consent to any departure by the Borrower therefrom shall in any event be effective unless the 

					
		  	38	  	  
 Revolving Loan Agreement

 
same shall be permitted by paragraph (b) of this Section, and then such waiver or consent shall be effective only in the specific instance and for the
purpose for which given. Without limiting the generality of the foregoing, the making of a Loan shall not be construed as a waiver of any Default, regardless of whether the Administrative Agent or any Lender may have had notice or knowledge of such
Default at the time. 
 (b) Amendments. Neither this Agreement nor any provision hereof may be waived, amended or
modified except pursuant to an agreement or agreements in writing entered into by the Borrower and the Required Lenders or by the Borrower and the Administrative Agent with the consent of the Required Lenders; provided that no such agreement
shall (i) increase the Commitment of any Lender without the written consent of such Lender, (ii) reduce the principal amount of any Loan or reduce the rate of interest thereon, or reduce any fees payable hereunder, without the written
consent of each Lender adversely affected thereby, (iii) postpone the scheduled date of payment of the principal amount of any Loan, or any interest thereon, or any fees payable hereunder, or reduce the amount of, waive or excuse any such
payment, or postpone the scheduled date of expiration of any Commitment, without the written consent of each Lender adversely affected thereby, (iv) alter the provisions of clause (c) or (d) of
Section 2.15 in a manner that would alter the pro rata sharing of payments required thereby, without the written consent of each Lender, or (v) change any of the provisions of this Section or the percentage in the definition
of the term “Required Lenders” or any other provision hereof specifying the number or percentage of Lenders required to waive, amend or modify any rights hereunder or make any determination or grant any consent hereunder, without
the written consent of each Lender; and provided further that no such agreement shall amend, modify or otherwise affect the rights or duties of the Administrative Agent hereunder without the prior written consent of the Administrative Agent.

 Anything in this Agreement to the contrary notwithstanding, no waiver or modification of any provision of this Agreement
that has the effect (either immediately or at some later time) of enabling the Borrower to satisfy a condition precedent to the making of a Loan shall be effective against the Lenders for purposes of the Commitments unless the Required Lenders shall
have concurred with such waiver or modification. 
 For purposes of this Section, the “scheduled date of
payment” of any amount shall refer to the date of payment of such amount specified in this Agreement, and shall not refer to a date or other event specified for the mandatory or optional prepayment of such amount. In addition, whenever a
waiver, amendment or modification requires the consent of a Lender “adversely affected” thereby, such waiver, amendment or modification shall, upon consent of such Lender, become effective as to such Lender whether or not it becomes
effective as to any other Lender, so long as the Required Lenders consent to such waiver, amendment or modification as provided above. 
 SECTION 9.03. Expenses; Indemnity; Damage Waiver. 
 (a) Costs and Expenses. The Borrower shall
pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent and its Affiliates, including the reasonable fees, charges and disbursements of counsel for the Administrative Agent, in connection with the syndication of the
credit facilities provided for herein, the preparation and administration of this Agreement or any amendments, modifications or waivers of the provisions hereof (whether or not the transactions contemplated hereby or thereby shall be consummated)
and (ii) all out-of-pocket expenses incurred by the Administrative Agent or any Lender, including the fees, charges and disbursements of any counsel for the Administrative Agent or any Lender, in connection with the 

					
		  	39	  	  
 Revolving Loan Agreement

 
enforcement or protection of its rights in connection with this Agreement and the other Loan Documents, including its rights under this Section, or in
connection with the Loans made hereunder, including in connection with any workout, restructuring or negotiations in respect thereof. 
 (b) Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent and each Lender, and each Related Party of any of the foregoing Persons (each such Person being called an
“Indemnitee”) against, and to hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses, including the fees, charges and disbursements of any counsel for any Indemnitee,
incurred by or asserted against any Indemnitee arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement or any agreement or instrument contemplated hereby, the performance by the parties hereto of
their respective obligations hereunder or the consummation of the Transactions or any other transactions contemplated hereby, (ii) any Loan or the use of the proceeds therefrom, (iii) any actual or alleged presence or release of Hazardous
Materials on or from any property owned or operated by the Borrower or any of its Subsidiaries, or any Environmental Liability related in any way to the Borrower or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation,
investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory and regardless of whether any Indemnitee is a party thereto; provided that such indemnity shall not, as to any Indemnitee, be
available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of
such Indemnitee. 
 (c) Reimbursement by Lenders. To the extent that the Borrower fails to pay any amount required to
be paid by it to the Administrative Agent under paragraph (a) or (b) of this Section, each Lender severally agrees to pay to the Administrative Agent such Lender’s Applicable Percentage (determined as of the time that the applicable
unreimbursed expense or indemnity payment is sought) of such unpaid amount; provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the
Administrative Agent in its capacity as such. 
 (d) Waiver of Consequential Damages, Etc. To the extent permitted by
applicable law, the Borrower shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in
connection with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the Transactions, any Loan or the use of the proceeds thereof. 
 (e) Payments. All amounts due under this Section shall be payable promptly after written demand therefor. 
 SECTION 9.04. Successors and Assigns. 
 (a) Assignments Generally. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that
(i) the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of each Lender (and any attempted assignment or transfer by the Borrower without such consent shall be null and
void) and (ii) no Lender may assign or otherwise transfer its rights or obligations hereunder except in accordance with this Section 9.04. Nothing in this Agreement, expressed or implied, shall be construed to 

					
		  	40	  	  
 Revolving Loan Agreement

 
confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants (to the extent provided in
paragraph (c) of this Section) and, to the extent expressly contemplated hereby, Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 (b) Assignments by Lenders. 
 (i) Assignments Generally. Subject to the conditions set forth in clause (ii) below, any Lender may assign to
one or more assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it) with the prior written consent (such consent not to be unreasonably
withheld or delayed) of: 
 (A) the Borrower, provided that no consent of the Borrower shall be required for an assignment to
a Lender, an Affiliate of a Lender, an Approved Fund or, if an Event of Default under clause (a), (b), (h) or (i) of Article VII shall have occurred and is continuing,
any other assignee; and 
 (B) the Administrative Agent, provided that no consent of the Administrative Agent shall be
required for an assignment of any Commitment to an assignee that is a Lender with a Commitment immediately prior to giving effect to such assignment. 
 (ii) Certain Conditions to Assignments. Assignments shall be subject to the following additional conditions: 
 (A) except in the case of an assignment to a Lender or an Affiliate of a Lender or an assignment of the entire remaining amount of the assigning Lender’s Commitment or Loans, the amount of the Commitment or Loans
of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent) shall not be less than $5,000,000 unless each of the Borrower
and the Administrative Agent otherwise consent, provided that no such consent of the Borrower shall be required if an Event of Default under clause (a), (b), (h) or (i) of
Article VII has occurred and is continuing; 
 (B) each partial assignment of any Commitment or Loans shall be
made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement in respect of such Commitment and Loans; 
 (C) the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption in substantially
the form of Exhibit A hereto, together with a processing and recordation fee of $3,500; and 
 (D) the
assignee, if it shall not already be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. 
 (iii) Effectiveness of Assignments. Subject to acceptance and recording thereof pursuant to paragraph (c) below, from and after the effective date specified in each Assignment and Assumption the assignee thereunder shall be a
party hereto and, to 

					
		  	41	  	  
 Revolving Loan Agreement

 
the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning
Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s
rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the rights referred to in Sections 2.12, 2.13, 2.14 and 9.03). Any
assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 9.04 shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such
rights and obligations in accordance with paragraph (e) below. 
 (c) Maintenance of Register by the Administrative
Agent. The Administrative Agent, acting for this purpose as an agent of the Borrower, shall maintain at one of its offices in San Francisco, California a copy of each Assignment and Assumption delivered to it and a register for the recordation
of the names and addresses of the Lenders, and the Commitment of, and principal amount of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be
conclusive, and the Borrower, the Administrative Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the
contrary. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice. 
 (d) Effectiveness of Assignments. Upon its receipt of a duly completed Assignment and Assumption executed by an assigning Lender
and an assignee, the assignee’s completed Administrative Questionnaire (unless the assignee shall already be a Lender hereunder), the processing and recordation fee referred to in paragraph (b) above and any written consent to such
assignment required by said paragraph (b), the Administrative Agent shall accept such Assignment and Assumption and record the information contained therein in the Register. No assignment shall be effective for purposes of this Agreement unless it
has been recorded in the Register as provided in this paragraph (d). 
 (e) Participations. Any Lender may, without the
consent of the Borrower or the Administrative Agent sell participations to one or more banks or other financial institutions (a “Participant”) in all or a portion of such Lender’s rights and obligations under this
Agreement and the other Loan Documents (including all or a portion of its Commitment and the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement and the other Loan Documents shall remain unchanged,
(ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent and the other Lenders shall continue to deal solely and directly with
such Lender in connection with such Lender’s rights and obligations under this Agreement and the other Loan Documents. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain
the sole right to enforce this Agreement and the other Loan Documents and to approve any amendment, modification or waiver of any provision of this Agreement or any other Loan Document; provided that such agreement or instrument may provide
that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver described in the first proviso to Section 9.02(b) that affects such Participant. Subject to paragraph
(f) below, the Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.12, 2.13 and 2.14 to the same extent as if it were a Lender and had acquired its interest by
assignment pursuant to paragraph (b) above. To the extent 

					
		  	42	  	  
 Revolving Loan Agreement

 
permitted by law, each Participant also shall be entitled to the benefits of Section 9.08 hereof as though it were a Lender,
provided such Participant agrees to be subject to Section 2.15(d) as though it were a Lender hereunder. 
 (f) Limitations on Rights of Participants. A Participant shall not be entitled to receive any greater payment under Section 2.12 or 2.14 than the applicable Lender would have been entitled to receive
with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent. A Participant that would be a Foreign Lender if it were a Lender shall not
be entitled to the benefits of Section 2.14 unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply with
Section 2.14(e) as though it were a Lender. 
 (g) Certain Pledges. Any Lender may at any time
pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any such pledge or assignment to a Federal Reserve Bank, and this Section 9.04 shall not
apply to any such pledge or assignment of a security interest; provided that no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such assignee for such Lender as a
party hereto. 
 (h) No Assignments to the Borrower or Affiliates. Anything in this Section to the contrary
notwithstanding, no Lender may assign or participate any interest in any Loan held by it hereunder to the Borrower or any of its Affiliates or Subsidiaries without the prior consent of each Lender. 
 SECTION 9.05. Survival. All covenants, agreements, representations and warranties made by the Borrower herein and in the certificates or
other instruments delivered in connection with or pursuant to this Agreement shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of this Agreement and the making of any Loans,
regardless of any investigation made by any such other party or on its behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default or incorrect representation or warranty at the time any
credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other amount payable under this Agreement is outstanding and unpaid and so long as the
Commitments have not expired or terminated. The provisions of Sections 2.12, 2.13, 2.14 and 9.03 and Article VIII shall survive and remain in full force and effect regardless of
the consummation of the transactions contemplated hereby, the repayment of the Loans, the expiration or termination of the Commitments or the termination of this Agreement or any provision hereof. 
 SECTION 9.06. Counterparts; Integration; Effectiveness. This Agreement may be executed in counterparts (and by different parties hereto on
different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement and any separate letter agreements with respect to fees payable to the Administrative Agent
constitute the entire contract between and among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in
Section 4.01, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof which, when taken together, bear the
signatures of each of the other parties hereto, and thereafter shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. Delivery of an executed counterpart of a signature page to this
Agreement by telecopy shall be effective as delivery of a manually executed counterpart of this Agreement. 

					
		  	43	  	  
 Revolving Loan Agreement

 SECTION 9.07. Severability. Any provision of this Agreement held to be invalid, illegal or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of the remaining provisions hereof; and the
invalidity of a particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction. 
 SECTION 9.08. Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender and each of its Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by
law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other obligations at any time owing by such Lender or Affiliate to or for the credit or the account of the Borrower
against any of and all the obligations of the Borrower now or hereafter existing under this Agreement held by such Lender, irrespective of whether or not such Lender shall have made any demand under this Agreement and although such obligations may
be unmatured. The rights of each Lender under this Section are in addition to other rights and remedies (including other rights of setoff) which such Lender may have. 
 SECTION 9.09. Governing Law; Jurisdiction; Etc. 
 (a) GOVERNING LAW.
THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF TEXAS. 
 (b) SUBMISSION TO
JURISDICTION. THE BORROWER HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE NONEXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF TEXAS SITTING IN DALLAS COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE
NORTHERN DISTRICT OF TEXAS, DALLAS DIVISION, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH
OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH TEXAS STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY LAW, IN SUCH FEDERAL COURT.
EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT SHALL
AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT OR ANY LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT AGAINST THE BORROWER OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. 
 (c) WAIVER OF VENUE. THE BORROWER HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND
EFFECTIVELY DO SO, ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY COURT REFERRED TO IN PARAGRAPH (b) OF THIS SECTION. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. 

					
		  	44	  	  
 Revolving Loan Agreement

 (d) Service of Process. Each party to this Agreement irrevocably consents to
service of process in the manner provided for notices in Section 9.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by law. 
 SECTION 9.10. Waiver of Jury Trial. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES
THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER
PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 
 SECTION 9.11. Headings. Article and Section headings and the Table of Contents used herein are for convenience of reference only, are not part of this Agreement and shall not affect the construction of, or be taken into
consideration in interpreting, this Agreement. 
 SECTION 9.12. Treatment of Certain Information; Confidentiality. 

(a) Treatment of Certain Information. The Borrower acknowledges that from time to time financial advisory, investment banking
and other services may be offered or provided to the Borrower or one or more of its Subsidiaries (in connection with this Agreement or otherwise) by any Lender or by one or more subsidiaries or affiliates of such Lender and the Borrower hereby
authorizes each Lender to share any information delivered to such Lender by the Borrower and its Subsidiaries pursuant to this Agreement, or in connection with the decision of such Lender to enter into this Agreement, to any such subsidiary or
affiliate, it being understood that any such subsidiary or affiliate receiving such information shall be bound by the provisions of paragraph (b) of this Section as if it were a Lender hereunder. Such authorization shall survive the repayment
of the Loans, the expiration or termination of the Commitments or the termination of this Agreement or any provision hereof. 
 (b) Confidentiality. Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (i) to its and its Affiliates’
directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed
to keep such Information confidential), (ii) to the extent requested by any regulatory authority, (iii) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (iv) to any other party to
this Agreement, (v) in connection with the exercise of any remedies hereunder or under any other Loan Document or any suit, action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or
thereunder, (vi) subject to an agreement containing provisions substantially the same as those of this Section, to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations
under this Agreement or (B) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (vii) with the consent of the Borrower or (viii) to the extent
such Information (A) becomes publicly available other than as a result of a breach of this Section or (B) becomes 

					
		  	45	  	  
 Revolving Loan Agreement

 
available to the Administrative Agent or any Lender on a nonconfidential basis from a source other than the Borrower. For the purposes of this Section,
“Information” means all information received from the Borrower relating to the Borrower or its business, other than any such information that is available to the Administrative Agent or any Lender on a nonconfidential basis
prior to disclosure by the Borrower; provided that, in the case of information received from the Borrower after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the
confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person
would accord to its own confidential information. 
 SECTION 9.13. USA Patriot Act. Each Lender hereby notifies the Borrower
that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107 56 (signed into law October 26, 2001)), such Lender may be required to obtain, verify and record information that identifies the Borrower, which information
includes the name and address of the Borrower and other information that will allow such Lender to identify the Borrower in accordance with said Act. 
 SECTION 9.14. Interest Rate Limitation. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts which
are treated as interest on such Loan under applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received
or reserved by the Lender holding such Loan in accordance with applicable law, the rate of interest payable in respect of such Loan hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the
extent lawful, the interest and Charges that would have been payable in respect of such Loan but were not payable as a result of the operation of this Section shall be cumulated and the interest and Charges payable to such Lender in respect of other
Loans or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Effective Rate to the date of repayment, shall have been received by such Lender.

 SECTION 9.15. ENTIRE AGREEMENT. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS REPRESENT THE FINAL AGREEMENT AMONG THE PARTIES AND
MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES. 
 [REMAINDER OF PAGE INTENTIONALLY BLANK; 
 SIGNATURE PAGES TO FOLLOW.] 

					
		  	46	  	  
 Revolving Loan Agreement

 Signature Page to that certain Revolving Loan Agreement dated as of January 18, 2008, among
Harte-Hanks, Inc., as Borrower, and Wells Fargo Bank, National Association, as Administrative Agent, Sole Lead Arranger and Sole Bookrunner, and certain Lenders named therein. 
  

			
	BORROWER:
	
	HARTE-HANKS, INC., as Borrower
		
	By:	 	 /s/ Douglas Shepard

		 	 Douglas Shepard, Executive Vice President
 and Chief
Financial Officer

 Signature Page to Revolving Loan Agreement 

			
	ADMINISTRATIVE AGENT:
	
	 WELLS FARGO BANK, NATIONAL
 ASSOCIATION, as the Administrative Agent
 and a Lender

		
	By:	 	 /s/ Greg D. Campbell

		 	Greg D. Campbell, Vice President

 Signature Page to Revolving Loan Agreement 

 SCHEDULE I 
 Commitments 
 [See Section 1.01] 
  

							
	 Lenders
	  	Commitment Amount	  	Applicable Percentage	 
	 Wells Fargo Bank, National Association
	  	$	50,000,000	  	100.000000000	%

 Schedule I 

 SCHEDULE II 
 Certain Agreements and Liens 
 [See Sections 3.13 and 6.01(b)] 
 Part A - Material Agreements 
 Borrower’s
Letters of Credit in excess of $10,000,000: 
  

										
	 Bank
	  	Amount	  	Beneficiary	  	Expiration	  	Autorenewal
	 Wells Fargo
	  	$	10,100,000.00	  	Travelers Indemnity	  	9/30/08	  	Yes
	 Wells Fargo
	  	$	10,714,741.00	  	Ace American Insurance	  	10/1/08	  	Yes

 Borrower’s Five-Year Revolving Line of Credit in excess of $10,000,000: 
  

						
	 Available
	  	Outstanding	  	Expiration
	 $125,000,000.00
	  	$	69,000,000.00	  	8/12/10

 Borrower’s Term Loan Agreement: 
  

						
	 Available
	  	Outstanding	  	Expiration
	 $190,125,000.00
	  	$	190,125,000.00	  	9/06/11

 Part B – Liens 
 None. 
 Schedule II 

 SCHEDULE III 
 Litigation 
 [See Section 1.01—”Disclosed Matters”] 
 None. 
 Schedule III 

 SCHEDULE IV 
 Environmental Matters 
 [See Section 1.01 “Disclosed Matters”]

 None. 
 Schedule IV 

 SCHEDULE V 
 Subsidiaries 
 [See Section 3.14] 
  

						
	 Name of Entity
	  	Jurisdiction of
Organization	  	% Owned	 
	 Aberdeen Group, Inc.
	  	Massachusetts	  	100	%
	 Avellino Technologies, Inc.
	  	Delaware	  	100	%(7)
	 Global Address Inc.
	  	Utah	  	100	%(13)
	 Global Address Ltd
	  	United Kingdom	  	100	%(13)
	 Harte-Hanks CRM Services Belgium NV
	  	Belgium	  	100	%(2)
	 Harte-Hanks Data Services LLC
	  	Maryland	  	100	%
	 Harte-Hanks Data Technologies, Inc.
	  	Delaware	  	100	%
	 Harte-Hanks Direct, Inc.
	  	New York	  	100	%(10)
	 Harte-Hanks Direct Marketing/Baltimore, Inc.
	  	Maryland	  	100	%
	 Harte-Hanks Direct Marketing/Cincinnati, Inc.
	  	Ohio	  	100	%
	 Harte-Hanks Direct Marketing/Dallas, Inc.
	  	Delaware	  	100	%(12)
	 Harte-Hanks Direct Marketing/Fullerton, Inc.
	  	California	  	100	%
	 Harte-Hanks Direct Marketing/Jacksonville, LLC
	  	Delaware	  	100	%(8)
	 Harte-Hanks Direct Marketing/Kansas City, LLC
	  	Delaware	  	100	%(1)
	 Harte-Hanks do Brazil Consultoria e Servicos Ltda.
	  	Brazil	  	100	%(5)
	 Harte-Hanks Flyer, Inc.
	  	Delaware	  	100	%
	 Harte-Hanks Global Address Limited
	  	United Kingdom	  	100	%(9)
	 Harte-Hanks Market Intelligence, Inc.
	  	California	  	100	%
	 Harte-Hanks Market Intelligence Espana LLC
	  	Colorado	  	100	%
	 Harte-Hanks Market Intelligence Europe B.V.
	  	Netherlands	  	100	%
	 Harte-Hanks Market Intelligence GmbH
	  	Germany	  	100	%(4)
	 Harte-Hanks Market Intelligence Limited
	  	Ireland	  	100	%(4)
	 Harte-Hanks Market Intelligence SAS
	  	France	  	100	%(4)
	 Harte-Hanks Market Research, Inc.
	  	New Jersey	  	100	%
	 Harte-Hanks NDC, LLC
	  	Delaware	  	100	%
	 Harte-Hanks Philippines, Inc.
	  	Philippines	  	100	%
	 Harte-Hanks Postfuture, Inc.
	  	Delaware	  	100	%(12)
	 Harte-Hanks Print, Inc.
	  	New Jersey	  	100	%
	 Harte-Hanks Pty. Limited
	  	Australia	  	100	%(3)
	 Harte-Hanks Response Management/Austin, Inc.
	  	Delaware	  	100	%(12)
	 Harte-Hanks Response Management/Boston, Inc.
	  	Massachusetts	  	100	%
	 Harte-Hanks Shoppers, Inc.
	  	California	  	100	%
	 Harte-Hanks SRL
	  	Romania	  	100	%(9)
	 Harte-Hanks Stock Plan, Inc.
	  	Delaware	  	100	%
	 Harte-Hanks STS, Inc.
	  	Delaware	  	100	%
	 Harte-Hanks Teleservices, LLC
	  	Delaware	  	100	%(6)
	 Harte-Hanks Trillium Software Germany GmbH
	  	Germany	  	100	%(11)
	 Harte-Hanks Trillium UK Limited
	  	United Kingdom	  	100	%(9)
	 Harte-Hanks UK Limited
	  	United Kingdom	  	100	%(3)
	 HTS, Inc.
	  	Connecticut	  	100	%
	 NSO, Inc.
	  	Ohio	  	100	%
	 Optima Global Data Services Limited
	  	United Kingdom	  	100	%(13)
	 Sales Support Services, Inc.
	  	New Jersey	  	100	%
	 Southern Comprint Co.
	  	California	  	100	%

	 (1)
	 Owned by Sales Support Services, Inc. 

					
		  		  	  
 Schedule V

	 (2)
	 99.84% Owned by
Harte-Hanks, Inc. 

 0.16% Owned by Harte-Hanks Direct, Inc. 

	 (3)
	 Owned by Harte-Hanks Data Technologies, Inc. 

	 (4)
	 Owned by Harte-Hanks Market Intelligence Europe B.V.

	 (5)
	 99.999% Owned by Harte-Hanks Data Technologies, Inc.

 .001% Owned by Harte-Hanks Stock Plan, Inc. 

	 (6)
	 Owned by Harte-Hanks Direct, Inc. 

	 (7)
	 Owned by Harte-Hanks Trillium UK Limited 

	 (8)
	 Owned by Harte-Hanks Direct Marketing/Cincinnati, Inc.

	 (9)
	 Owned by Harte-Hanks UK Limited 

	 (10)
	 Owned by Harte-Hanks Print, Inc. 

	 (11)
	 Owned by Harte-Hanks Market Intelligence GmbH 

	 (12)
	 Owned by Harte-Hanks Stock Plan, Inc. 

	 (13)
	 Owned by Harte-Hanks Global Address Limited 

					
		  	2	  	  
 Schedule V

 EXHIBIT A 
 ASSIGNMENT AND ASSUMPTION 
 This Assignment and Assumption (the “Assignment and Assumption”) is
dated as of the Effective Date set forth below and is entered into by and between [Insert name of Assignor] (the “Assignor”) and [Insert name of Assignee] (the “Assignee”). Capitalized terms used but
not defined herein shall have the meanings given to them in the Loan Agreement identified below (as amended, the “Loan Agreement”), receipt of a copy of which is hereby acknowledged by the Assignee. The Standard Terms and
Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full. 
 For an agreed consideration, the Assignor hereby irrevocably sells and assigns to the Assignee, and the Assignee hereby irrevocably purchases and assumes
from the Assignor, subject to and in accordance with the Standard Terms and Conditions and the Loan Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of the Assignor’s rights and
obligations in its capacity as a Lender under the Loan Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and
obligations of the Assignor under the respective facilities identified below and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of the Assignor (in its capacity as a
Lender) against any Person, whether known or unknown, arising under or in connection with the Loan Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related
to any of the foregoing, including contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above
(the rights and obligations sold and assigned pursuant to clauses (i) and (ii) above being referred to herein collectively as the “Assigned Interest”). Such sale and assignment is without
recourse to the Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by the Assignor. 
  

					
	1.	  	Assignor:	  	__________________________________
			
	2.	  	Assignee:	  	__________________________________
		  		  	[and is an Affiliate/Approved Fund of [identify Lender]1]
			
	3.	  	Borrower(s):	  	Harte-Hanks, Inc.
			
	4.	  	Administrative Agent:	  	Wells Fargo Bank, National Association, as the administrative agent under the Loan Agreement
			
	5.	  	Loan Agreement:	  	The Revolving Loan Agreement dated as of January 18, 2008 among Harte-Hanks, Inc., the Lenders parties thereto, and Wells Fargo Bank, National Association, as Administrative
Agent

	 1
	 Select as applicable. 

					
		  		  	  
 Exhibit A

	6.	Assigned Interest: 

  

							
	 Facility Assigned
	  	 Aggregate Amount of
Commitments/Loans for
 all Lenders
	  	 Amount of
 Commitment/Loans
 Assigned
	  	 Percentage Assigned of
Commitment/Loans
 (set forth, to at least 9
 decimals,
as a
 percentage of the
 Commitments/Loans of
 all Lenders thereunder)

	 Commitment Assigned
	  	$                            	  	$                        	  	%
	 Loans
	  	$                            	  	$                        	  	%
	 Fees Assigned (if any):
	  	$                            	  	$                        	  	%

 Effective Date:             
    , 20     [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.] 
 The terms set forth in this Assignment and Assumption are hereby agreed to: 
  

			
	ASSIGNOR
	
	[NAME OF ASSIGNOR]
		
	By:	 	  

	Title:	 	
	
	ASSIGNEE
	
	[NAME OF ASSIGNEE]
		
	By:	 	  

	Title:	 	

 Exhibit A 
  

 2 

			
	Consented to and Accepted:
	
	 WELLS FARGO BANK, NATIONAL
 ASSOCIATION, as Administrative Agent

		
	By	 	  

	Title:	 	
	
	Consented to:
	
	HARTE-HANKS, INC.
		
	By	 	  

	Title:	 	

 Exhibit A 
  

 3 

 ANNEX 1 
 STANDARD TERMS AND CONDITIONS FOR 
 ASSIGNMENT AND ASSUMPTION 
 1. Representations and Warranties. 
 1.1 Assignor. The Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of the Assigned Interest, (ii) the Assigned Interest is free and clear of any lien, encumbrance or other adverse
claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes no responsibility with
respect to (i) any statements, warranties or representations made in or in connection with the Loan Agreement, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Agreement or any
collateral thereunder, (iii) the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in respect of the Loan Agreement or (iv) the performance or observance by the Borrower, any of its
Subsidiaries or Affiliates or any other Person of any of their respective obligations under the Loan Agreement. 
 1.2. Assignee. The
Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a
Lender under the Loan Agreement, (ii) it satisfies the requirements, if any, specified in the Loan Agreement that are required to be satisfied by it in order to acquire the Assigned Interest and become a Lender, (iii) from and after the
Effective Date, it shall be bound by the provisions of the Loan Agreement as a Lender thereunder and, to the extent of the Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it has received a copy of the Loan Agreement,
together with copies of the most recent financial statements delivered pursuant to Section 5.01 thereof, as applicable, and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter
into this Assignment and Assumption and to purchase the Assigned Interest on the basis of which it has made such analysis and decision independently and without reliance on the Administrative Agent or any other Lender, (v) if it is a Foreign
Lender, attached to the Assignment and Assumption is any documentation required to be delivered by the Assignee pursuant to Section 2.14(e) of the Loan Agreement, duly completed and executed by the Assignee, and (vi) if it is
not already a Lender under the Loan Agreement, an Administrative Questionnaire in the form supplied by the Administrative Agent, duly completed by the Assignee; and (b) agrees that (i) it will, independently and without reliance on the
Administrative Agent, the Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Agreement, and
(ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Agreement are required to be performed by it as a Lender. The [Assignee/Assignor] shall pay the fee payable to the Administrative Agent
pursuant to Section 9.04(b) of the Loan Agreement. 
 2. Payments. From and after the Effective Date, the
Administrative Agent shall make all payments in respect of the Assigned Interest (including payments of principal, interest, fees and other amounts) to the Assignor for amounts which have accrued to but excluding the Effective Date and to the
Assignee for amounts which have accrued from and after the Effective Date. 
 3. General Provisions. This Assignment and Assumption
shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one 

					
		  		  	  
 Annex 1 to Exhibit A

 
instrument. Delivery of an executed counterpart of a signature page of this Assignment and Assumption by telecopy shall be effective as delivery of a
manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of Texas. 
  

					
		  	2	  	  
 Annex 1 to Exhibit A

 EXHIBIT B 
 Form of Opinion of Counsel to the Borrower 
 January 18, 2008 
 To the Lenders and the Administrative 
   Agent referred to below

 c/o Wells Fargo Bank, National Association, 
   as
Administrative Agent 
 1445 Ross Avenue, Suite 2320 
 Dallas,
Texas 75202 
 Ladies and Gentlemen: 
 We have acted as special
counsel to Harte-Hanks, Inc., a Delaware corporation (the “Borrower”), in connection with the Revolving Loan Agreement, dated as of January 18, 2008 (the “Loan Agreement”) between the Borrower, Wells Fargo Bank, National
Association, as Administrative Agent, and the Lenders party thereto. Capitalized terms not defined herein are used as defined in the Loan Agreement. This opinion is being delivered pursuant to Section 4.01(b) of the Loan Agreement. 

For purposes of this opinion, we have reviewed the Loan Agreement. We have also reviewed and relied upon the originals, or copies certified or otherwise identified to
our satisfaction, of corporate documents and records of the Borrower and certificates of public officials and officers of the Borrower and other documents, certificates, instruments and agreements as in our judgment are necessary to enable us to
deliver this opinion letter. As to questions of fact material to the opinions, we have relied upon information received from officers of the Borrower without independent verification. 
 In rendering our opinions, we have assumed: 
  

	 	(a.)	the genuineness and authenticity of all signatures to all documents submitted to us a originals (other than the Borrower’s signatures); 

  

	 	(b.)	the conformity to authentic original documents of all documents submitted to us as certified, conformed, or photostatic copies; 

  

	 	(c.)	the correctness and accuracy of all facts set forth in all certificates and documents delivered to us in connection with this opinion; 

  

	 	(d.)	the Loan Agreement is enforceable against all parties thereto (except as otherwise expressly stated with respect to the Borrower in Paragraph 4 of the opinions expressed below); and

					
		  		  	  
 Exhibit B

	 	(e.)	there are no agreements or understandings among the parties that would define, supplement or qualify the terms of the Loan Agreement. 

 Based upon and subject to the foregoing and subject also to the assumptions and qualifications set forth below, and having considered such questions of law as we have
deemed necessary as a basis for the opinions expressed below, we are of the opinion that: 
  

	 	1.	The Borrower is a validly existing corporation in good standing under the laws of the State of Delaware. The Borrower has the requisite corporate power and authority to carry on its
business as now conducted and, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, is qualified to do business in, and is in good standing in, every
jurisdiction where such qualification is required. 

  

	 	2.	The Transactions are within the corporate powers of the Borrower. 

  

	 	3.	The Transactions have been duly authorized by all necessary corporate action on the part of the Borrower. 

  

	 	4.	The Loan Agreement has been duly executed and delivered by the Borrower and constitutes the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in
accordance with its terms, except as may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or other similar laws relating to or affecting the enforcement of creditors’ rights in general and
subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law), including, without limitation, (a) the possible unavailability of specific performance, injunctive relief or
any other equitable remedy and (b) concepts of materiality, reasonableness, good faith and fair dealing. 

  

	 	5.	The Transactions (a) do not require, on the part of the Borrower, any consent or approval of, registration or filing with, or any other action by, any Governmental Authority
(except for any filings which are first required to be made with the Securities and Exchange Commission after the date hereof), (b) will not violate the charter or by-laws of the Borrower or, to our knowledge, any applicable law or regulation
or any order of any Governmental Authority applicable to the Borrower, (c) to our knowledge, will not violate or result in a default under any material indenture, agreement or other instrument binding upon the Borrower or any of its
Subsidiaries or assets, or give rise to a right thereunder to require any payment to be made by any such Person and (d) to our knowledge and except as provided in the Loan Documents, will not result in the creation or imposition of any Lien on
any asset of the Borrower or any of its Material Subsidiaries. 

  

	 	6.	To our knowledge, there are no actions, suits or proceedings by or before any arbitrator or Governmental Authority now pending against or threatened against or affecting the
Borrower or any of its Subsidiaries (a) as to which there is a reasonable possibility of an adverse determination and that, if adversely determined, could reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect (other than Disclosed Matters) or (b) that involve the Loan Agreement or the Transactions. 

  

	 	7.	The Borrower is not (a) an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940 or (b) a “holding
company” as defined in, or subject to regulation under, the Public Utility Holding Company Act of 1935. 

 The foregoing opinions are
subject to the following qualifications and exceptions: 
  

	 	(a.)	The foregoing opinions are limited to the Federal laws of the United States of America, the General Corporation Law of the State of Delaware and Texas law. 

					
		  	2	  	  
 Exhibit B

	 	(b.)	The qualification of any opinion or statement herein by the use of the words “to our knowledge”, “known to us” or words of similar import means that during the
course of our representation as described herein, no information has come to the attention of the attorneys in this firm directly involved in the transactions described herein which gave such attorneys actual knowledge contrary to the position
stated. 

  

	 	(c.)	In rendering the opinion set forth in Paragraph 5 hereof, we have reviewed only (i) those statutes and regulations that a lawyer in the State of Texas exercising customary
professional diligence would reasonably recognize as being directly applicable to the Borrower and the transactions contemplated by the Loan Agreement and (ii) those indentures, agreements and instruments set forth on the Exhibit Index to the
Borrower’s Annual Report on Form 10-K for the year ended December 31, 2006. 

  

	 	(d.)	We express no opinion with respect to any provision contained in the Loan Agreement prohibiting oral amendments to or waivers of provisions of such documents or limiting the effect
of a course of dealing between the parties thereto. 

  

	 	(e.)	This opinion letter is limited to the matters stated herein as of the date hereof and is limited to present statutes, rules, laws and regulations and to the facts as they currently
exist. We assume no obligation to update this opinion letter or to advise you of any changes in our opinions in the event of changes in applicable law or facts becoming effective or occurring after the date hereof or if additional newly discovered
information is brought to our attention after the date hereof. 

  

	 	(f.)	We express no opinion as to usury laws. 

  

	 	(g.)	The opinions set forth in Paragraph 4 of this opinion letter to the extent covering Texas law, are also subject to the effect of generally applicable rules of Texas law that:

  

	 	(i)	provide forum selection clauses in contracts are not necessarily binding on the court(s) in the forum selected; 

  

	 	(ii)	limit the enforceability of provisions releasing, exculpating or exempting a party from, or requiring indemnification of a party for, liability for its own action or inaction, to
the extent the action or inaction involves gross negligence, recklessness, willful misconduct or unlawful conduct; 

  

	 	(iii)	may permit a party who has materially failed to render or offer performance required by the contract to cure that failure unless (i) permitting a cure would unreasonably hinder
the aggrieved party from making substitute arrangements for performance, or (ii) it was important in the circumstances to the aggrieved party that performance occur by the date stated in the contract; 

  

	 	(iv)	impose limitations on attorneys’ or trustees’ fees; 

  

	 	(v)	limit or affect the enforceability of provisions for late charges, prepayment charges, or yield maintenance charges, acceleration of future amounts due (other than principal)
without appropriate discount to present value, liquidated damages, and “penalties”; 

					
		  	3	  	  
 Exhibit B

	 	(vi)	limit or affect the enforceability of provisions that provide for the acceleration of indebtedness upon any transfer or change in the control, ownership, or management of any party;
and 

  

	 	(vii)	limit or affect the enforcement of provisions of a contract that purport to require waiver of jury trial. 

 This opinion letter is delivered to you solely for your benefit in connection with the Loan Agreement. This opinion letter may not be relied on by you for any other
purpose, nor may it be furnished to, used by, circulated to, quoted to or referred to by, any other person for any purpose without our prior express written consent. 
 Circular 230 disclosure: Pursuant to Department of Treasury Circular 230, this correspondence is not intended or written to be used, and may not be used by the recipient, for the purposes of avoiding any federal tax
penalty which may be asserted. 
 Sincerely yours, 
 Cox Smith
Matthews Incorporated 

					
		  	4	  	  
 Exhibit BSublicense Agreement

 Exhibit 10.1 
 SUBLICENSE AGREEMENT 
 BETWEEN 
 REVIMMUNE, LLC 
 AND 
 BIOVEST INTERNATIONAL, INC. 
 This Sublicense Agreement
(this “Agreement or “Sublicense Agreement”) effective as of January 16, 2008, by and between REVIMMUNE, LLC, a Florida limited liability company, (“REVIMMUNE”), and BIOVEST INTERNATIONAL, INC., a Delaware
corporation, (“BIOVEST”) (collectively the “Parties”). 
 WITNESSETH: 
 Whereas, REVIMMUNE has received an exclusive worldwide license to certain rights arising from U.S. Provisional Patent Applications Serial No. 60/742,172, filed on
December 2nd, 2005, entitled “Use of High-dose Oxazaphosphorine Drugs for Treating Immune Disorders”, along with associated know-how, as specifically defined in the License Agreement from Johns Hopkins
University (the “JHU License”) attached hereto as Exhibit A (the “ Revimmune Licensed Rights”); 
 Whereas, the founders of REVIMMUNE
began negotiating with various personnel at JHU for the potential acquisition of the Revimmune Licensed Rights in 2003; 
 Whereas, the founder of REVIMMUNE
obtained a Notice of Allowance for the trade name “REVIMMUNE” ON March 25, 2003; 
 Whereas, REVIMMUNE was organized as a limited liability
company by filing articles of organization with the State of Florida on January 16, 2006; 
 Whereas, BIOVEST recognizes that the REVIMMUNE Licensed
Rights are valuable for drug development, use and/or sale in the treatment or prevention of human diseases; 
 Whereas, BIOVEST wishes to enter into an
agreement to obtain an exclusive sublicense to the Sublicensed Products from REVIMMUNE in order to develop, promote, market and commercialize prophylactic and/or therapeutic products or treatments for the prevention of transplant rejection including
rejection following a bone marrow transplant. 
 Whereas, the Revimmune License names BIOVEST as an affiliate of REVIMMUNE for all purposes under the
Revimmune License; and 
 WHEREAS, REVIMMUNE is willing to grant such sublicense to BIOVEST under the terms and conditions set forth in this Agreement.

 NOW, THEREFORE, in consideration of the various promises and undertakings set forth herein, the Parties agree as follows:

 ARTICLE 1—DEFINITIONS 
 Capitalized terms, not otherwise defined herein shall have the meaning assigned to them in the JHU License. For purposes of this Agreement, the following terms shall have the meanings set forth below: 
  

	1.1	“Effective Date” shall mean the date first written above. 

  

	1.2	“Territory” shall mean worldwide. 

  

	1.3	“Field” shall mean the treatment of and prevention of transplant rejection including rejection following a bone marrow transplant and specifically shall not include
indications for any other diseases or treatments. 

  

	1.4	“Sublicensed Rights” shall mean the Revimmune Licensed Rights plus any intellectual property rights acquired by REVIMMUNE either prior to the date of this Agreement or
hereafter during the term of this Agreement (whether acquired from JHU, another third party, or through internal development activities) specifically limited to the Field and the Sublicensed Indications. 

  

	1.5	“Sublicensed Products” shall mean any materials, compositions, drugs, or other products, methods or services which are in material part first identified, discovered, made,
or commercialized by practicing one or more valid claims included in the patents that are part of the Sublicensed Rights specifically limited to the Field and the Sublicensed Indications. 

  

	1.6	“Sublicense Indications” shall mean the treatment of and prevention of transplant rejection including rejection following a bone marrow transplant and specifically shall
not include indications for other diseases or treatments. For clarification, treatments for all forms of autoimmunity, including but not limited to MS, are excluded from the definition of Sublicense Indications. 

  

	1.7	“Sublicensed Royalty” shall have the meaning set forth in Article 4 hereof. 

  

	1.8	“Revimmune Licensed Rights” shall mean the rights granted to REVIMMUNE in the JHU License. 

  

	1.9	“JHU License” shall mean the License Agreement between Johns Hopkins University and REVIMMUNE attached hereto as Exhibit A. 

  

	1.10	“JHU” shall mean John Hopkins University. 

  

	1.11	“Affiliate” shall mean, with respect to a specified person or entity, any other person or entity that controls, is controlled by, or is under common control (whether
through equity ownership, contract, or otherwise) the specified person or entity. 

  

 2 

 ARTICLE 2—REPRESENTATIONS AND WARRANTIES; 
 RESPONSIBILITIES OF THE PARTIES 
  

	2.1	Representations and Warranties of Both Parties. Each Party represents and warrants to the other Party that: (i) it is free to enter into this Sublicense Agreement;
(ii) in so doing, it will not violate any other agreement to which it is a party; and (iii) it has taken all corporate action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under
this Agreement. 

  

	2.2	Representations and Warranties of REVIMMUNE. REVIMMUNE hereby represents and warrants that: 

 (a) The JHU License is in full force and effect, and REVIMMUNE has the right to grant the sublicense there under without the consent or
approval of any third party; 
 (b) To the best of REVIMMUNE’s knowledge, all the REVIMMUNE Licensed Rights listed in the
JHU License attached as Exhibit A are in full force and effect and have been maintained to date; 
 (c) REVIMMUNE is not aware
of any asserted or unasserted claim or demand against the REVIMMUNE Licensed Rights; 
 (d) None of the REVIMMUNE Licensed
Rights infringes upon any patent or other proprietary rights of any third party; and 
 (e) REVIMMUNE has not entered into any
agreement with any other entity which is in conflict with the rights granted to BIOVEST pursuant to this Sublicense Agreement. 
  

	2.3	Representations and Warranties of BIOVEST. BIOVEST hereby represents and warrants that: 

 (a) BIOVEST has the right to enter into this Sublicense Agreement without the consent of any third party; 
 (b) BIOVEST will exercise reasonable efforts to develop, promote, market, sell and commercialize the Sublicensed Rights for all Sublicense
Indications; 
 (c ) BIOVEST has no right in or to the JHU License or the Licensed Products except only those rights and
interest expressly granted hereunder and 
 (d) BIOVEST has acknowledged and waived any and all conflicts of interest rising
from or related in any fashion to this Sublicense Agreement including but not limited to the ownership and management of Revimmune. 
  

 3 

	2.4	Employee Agreements. Each Party warrants that it has, and covenants that it will have, entered into a proprietary information and inventions agreement with each of its
employees prior to the time that any such employee shall receive confidential information from a disclosing party under this Agreement or begin work related to this Agreement. Such agreement shall minimally set forth employee obligations to assign
inventions to the inventing Party and to maintain confidentiality of confidential information consistent with the terms of this Agreement. 

  

	2.5	REVIMMUNE Responsibilities. REVIMMUNE will be responsible to maintain the JHU License in full force and effect. 

  

	2.6	BIOVEST Responsibilities. 

 (a)
BIOVEST will be responsible, at its sole cost and expense, for the development, promotion, marketing, sales and commercialization of the Sublicensed Rights in connection with each of the Sublicense Indications. 
 (b) BIOVEST will during the term of this Sublicense Agreement use commercially reasonable efforts to continuously develop, promote, sale,
market and commercialize the Sublicensed Products for each of the Sublicense Indications. 
 (c) Subject to Section 3.3
and Article 6 hereof, BIOVEST shall share with REVIMMUNE all proprietary and clinical data and information related to the Sublicensed Products, Sublicensed Rights and any related clinical trial which data and information may be used by REVIMMUNE in
support of the development and commercialization of products for indications other than the Sublicense Indications. 
 (d)
BIOVEST shall maintain all information and data related to the Sublicensed Products and Sublicensed Rights confidential. 
 (e) BIOVEST shall not develop or commercialize any product or treatment that could reasonably be considered to be in competition with Revimmune Licensed Rights for indications other than the Sublicense Indications. 
 (f) BIOVEST shall promptly pay all Royalties required by this Sublicense Agreement. 
 (g) BIOVEST shall maintain insurance pursuant to Article 7 and shall cause such insurance to name REVIMMUNE as a coinsured. 
 ARTICLE 3—LICENSE GRANT 
  

	3.1	 Grant of License. Subject to the terms and conditions of this Agreement, REVIMMUNE hereby grants to BIOVEST an exclusive (including to the exclusion of
REVIMMUNE), perpetual sublicense to the Sublicensed Rights throughout the Territory, with the right to grant further sublicenses, to develop, promote, market, sell, make, have made, use, import, offer for sale, and commercialize the Sublicensed
Products for the Sublicense Indications in the Field and Territory. For clarification, BIOVEST shall have no rights under this Agreement to develop, promote, market, sell, make, have made, use, import, offer for sale or commercialize any product
based on or using the Sublicensed Rights for 

  

 4 

	 	 
the treatment of any disease, or for use in connection with, any indication other than the Sublicense Indications. The license grants in this paragraph shall
apply to BIOVEST and any of its Affiliates, and if any Affiliate of BIOVEST exercises rights under this Agreement, such Affiliate shall be bound by all the terms and payments, which shall apply to the exercise of the rights, to the same extent as
would apply had this Agreement been directly entered into between REVIMMUNE and such Affiliate. 

  

	3.2	Right to Grant Sublicenses. BIOVEST shall have the right to sublicense the Sublicensed Rights in the Territory with the prior written approval of REVIMMUNE, which approval
may not be unreasonably withheld, provided: (i) the sublicensee agrees to be bound by all terms and conditions of this Sublicense Agreement as amended, including, but not limited to, the payment of all royalties to REVIMMUNE as provided in
Article 4 as though BIOVEST itself had sold the Licensed Product (ii) BIOVEST guarantees the performance of all material provisions of this Sublicense Agreement by its sublicensee; (iii) at the time of the sublicense, BIOVEST is not in
breach or non-compliance with any material provision of this Sublicense Agreement, (iv) JHU consents in writing to the sublicense; (v) the sublicensee, in REVIMMUNE’s reasonable judgment, is reasonably capable of developing,
promoting, marketing, selling and commercializing the Sublicensed Products; (vi) the sublicensee, in REVIMMUNE’s reasonable judgment, is not a competitor of the Revimmune Licensed Rights; (vii) upon termination of this Sublicense
Agreement for any reason, the sublicense granted by BIOVEST shall revert directly to REVIMMUNE, which may at its election recognize or disaffirm such sublicense and (viii) all fees in connection with or resulting from the sublicense required by
the JHU License and by this Sublicense Agreement are paid by Biovest. Each sublicense granted by BIOVEST pursuant to this Agreement shall be consistent the provisions of this Agreement and the JHU License. Prior to the grant of each sublicense
hereunder, BIOVEST shall provide REVIMMUNE a copy of the sublicense. BIOVEST shall not grant any paid-up license or accept equity in consideration, directly or indirectly, for such sublicenses without REVIMMUNE’s written approval.

  

	3.3	Intellectual Property. Title to any and all New Intellectual Property developed solely through the efforts of the employees, agents, independent contractors, or joint venture
partners of one Party shall vest solely and exclusively in such Party, provided that any such New Intellectual Property owned by REVIMMUNE will become subject to the licenses granted in this Agreement and any such New Intellectual Property owned by
Biovest shall be licensed back to Revimmune on a royalty-free basis and exclusively for non-transplant rejection disease indications throughout the Territory. Any New Intellectual Property developed through the joint efforts of the employees,
agents, independent contractors, or joint venture partners of both Parties shall be owned jointly by the Parties, provided that any such jointly owned New Intellectual Property shall be subject to the licenses granted in this Agreement and any such
New jointly owned Intellectual Property shall be licensed back to Revimmune on a royalty-free basis and exclusively for non-transplant rejection disease indications throughout the Territory. “New Intellectual Property” shall mean any and
all inventions, know-how, developments, methods, processes, improvements, and other information relating to the Revimmune Licensed Rights, Sublicensed Rights, or Sublicensed Products in any form, technical or economic, patentable or unpatentable,
confidential or otherwise to the extent they are first conceived or developed by either Party or by both Parties after the date of this Agreement. 

  

 5 

	3.4	Rights of REVIMMUNE. REVIMMUNE shall, during the term of this Sublicense Agreement, have the absolute right, without notice to or consent from BIOVEST or its sublicensees,
to: (i) sublicense, assign, develop, promote, sell, market, commercialize or otherwise deal with the Licensed Rights for any or all indications or diseases other than the Sublicense Indications and (ii) enter into any amendment,
modification or restatement of the License Agreement between REVIMMUNE and JHU including an amendment or modification to the Revimmune License Rights, provided that none of the actions in foregoing clauses (i) or (ii) shall adversely
affect the rights of BIOVEST without BIOVEST’s prior written consent. 

 ARTICLE 4—ROYALTY AND OTHER PAYMENTS AND
REPORTS 
  

	4.1	License Fee. As consideration for entering into this Agreement, BIOVEST shall pay to REVIMMUNE ten (10) dollars within thirty (30) days of the Effective Date.

  

	4.2	Royalties. 

 (a) As consideration for the license
rights granted BIOVEST under this agreement, BIOVEST will pay REVIMMUNE a Fixed Royalty equal to six percent (6%) of Net Sales (as defined in the JHU License) of any Sublicensed Product (the “Sublicensed Royalty”) by BIOVEST, its
affiliates or sublicensees. The Fixed Royalty will not be payable on sales by BIOVEST to its Affiliates and will instead be applied to the sale of Sublicensed Products by such Affiliates. 
 (b) Royalty Stacking. In the event that a royalty is obligated to a third party, Biovest shall assume the full responsibility for any such royalty.

  

	4.3	Sublicense Fee. Upon a sublicense by BIOVEST, BIOVEST shall pay to REVIMMUNE an amount equal to 20% of the consideration received by BIOVEST for the sublicense (other than
sublicenses to Affiliates of BIOVEST). This fee shall not reduce the on going Royalty obligation under Section 4.2 above, which shall continue after the date of sublicense. This sublicense fee is in addition to the sublicense fee
required to be paid to JHU under the JHU License. 

  

	4.4	Fee at Product Approval. Upon FDA approval of each Sublicensed Product for sale or use in the U.S., BIOVEST shall issue to REVIMMUNE a vested warrant to purchase 2,000,000
shares of BIOVEST common stock at an exercise price of $1.10 per share (or, if higher, the fair market value of a share of BIOVEST common stock on the date of the issuance of the warrant, as determined by BIOVEST’s Board of Directors in its
reasonable judgment) subject to customary adjustment in the event of a stock dividend, stock split or other similar event for a term of seven years. For clarification, a separate warrant will be granted for each Sublicensed Product approved by the
FDA for sale or use in the US. 

  

 6 

	4.5	Relationship to JHU License and Payment of Royalties to JHU. The Parties acknowledge that, notwithstanding any terminology used in this Agreement to the contrary, BIOVEST is
a primary licensee (and not a sublicense) under the JHU License by virtue of the last two sentences of Section 2.1 of the JHU License. In addition to (and not in reduction of or in off-set of) BIOVEST’s obligations to Revimmune set forth
in this Article IV and Section 4.2 and Section 4.3, BIOVEST shall be responsible to pay (or reimburse Revimmune if Revimmune directly pays JHU) for all royalties resulting from sales or activities under this Sublicense Agreement that are
required to be paid to JHU under the License Agreement between Revimmune and JHU. BIOVEST’s obligations to pay royalties to JHU shall be in addition to BIOVEST’s obligations to pay Royalties and Sublicense Fees to Revimmune.

  

	4.6	Term of Royalty Obligations. The Sublicensed Royalty specified herein continue as to each Sublicensed Product in the Territory for the term of this Sublicense Agreement,
including any Extension Term hereof. 

  

	4.7	Date and Place of Sale. Sublicensed Products shall be considered sold when BIOVEST, an Affiliate or Sublicensee is paid by a purchaser for a Sublicensed Product.

  

	4.8	Monthly Report. On or before the tenth day of each calendar month commencing with the first to occur of the sale of any Sublicensed Product or the receipt by BIOVEST of any
Net Sale, BIOVEST shall provide a written Report of Sales reflecting the unit sales and Net Sales for each Sublicensed Product for each calendar month. 

  

	4.9	Payments by BIOVEST. Payments shall be made to REVIMMUNE on a monthly basis no later than thirty (30) days following the end of the month during which such payments
accrued. 

  

	4.10	Place of Payment. All payments due shall be payable in United States dollars by wire transfer to a bank account designated by each Party from time to time.

  

	4.11	Taxation of Payments. 

 (a) Insofar
as any payment that is due under this Agreement is subject to any tax, duty, levy, or other government imposition, the Party receiving the payment agrees to bear any and all such taxes, duties, levies or impositions. Each Party hereby authorizes the
other Party to withhold such taxes, duties, levies or impositions from the payments in accordance with this Agreement if BIOVEST or REVIMMUNE is required to do so under the laws of the United States. Whenever a Party deducts such tax, duty, levy or
imposition from any payments due, then it shall furnish the other Party with a certificate showing the payment of thereof to the United States. 
 (b) In the event any payments which are due to under this Agreement are subject to value added taxation by any government, then the Party receiving the payment shall bear such value added tax in full and the Party
making the payment shall be reimbursed therefore. If appropriate, the Party receiving payment may add such value 

  

 7 

 
added taxes to its royalty accounts, provided such value added taxes are credited against the other Party’s value added tax debt and the other Party is
reimbursed in full with respect thereto. Notwithstanding anything herein to the contrary, the Party making the payment shall have no liability for any value added tax directly or indirectly relating to thereto. 
 (c) In the event any payment is subject to a withholding or other income tax in the Territory, promptly following becoming aware of the applicability of
any such tax, the Party making the payment shall so advise the other Party. The Party receiving the payment shall have the right to contest with the appropriate governmental body any such proposed withholding and the other Party shall provide, at
receiving Party’s expense, reasonable cooperation in any such contest. The Parties shall provide each other with such receipts or other evidence of any tax withheld as is necessary to claim any credit or deduction available to it in other
jurisdictions. Payments shall only be reduced for withholding taxes imposed by the jurisdiction out of which the payment is directly made. 
  

	4.12	Interest. All payments due hereunder that are not paid when due and payable as specified in this agreement shall bear interest at an annual rate equal to the prime rate
(“Prime Rate”) for U.S. dollar deposits in effect from time to time, as published daily in the Wall Street Journal plus 2%, compounded monthly from the date due until paid, or at such lower rate of interest as shall then be the maximum
rate permitted by applicable law. 

  

	4.13	Right to Documentation. Upon request, REVIMMUNE shall have the right to request reasonable documentation of BIOVEST’s Sublicensed Royalty calculations to determine
BIOVEST’s Net Sales and/or Sublicensee Net Sales for the Sublicensed Products and to request discussion of such calculations with appropriate representatives of BIOVEST. 

  

	4.14	Records Retention. BIOVEST, its Sublicensee shall keep complete and accurate records pertaining to the sale of Sublicensed Products in the Territory and covering all
transactions which Net Sales are derived for a period of three (3) calendar years after the year in which such sales occurred, and in sufficient detail to permit REVIMMUNE to confirm the accuracy of royalty calculations hereunder. Such records
shall be available at all reasonable times for inspection by REVIMMUNE or its representatives for verification of royalty payments or compliance with other aspects of this Agreement. 

  

	4.15	 Audit Request. At the request of REVIMMUNE, BIOVEST, its Affiliates and Sublicensees shall permit an independent, certified public accountant appointed by
REVIMMUNE acceptable to BIOVEST, at reasonable times and upon reasonable notice, to examine those records and all other material documents relating to or relevant to Net Sales and Sublicensed Royalties in the possession or control of BIOVEST or
Sublicensees, for a period of three (3) years after such Sublicensed Royalties have accrued, as may be necessary to: (i) determine the correctness of any report or payment made under this Agreement; or (ii) obtain information as to
the Sublicensed Royalties payable for any calendar quarter in the case of BIOVEST’s or sublicense’s failure to 

  

 8 

 
report or pay pursuant to this Agreement. Said accountant shall not disclose to REVIMMUNE any information other than information relating to said reports,
royalties, and payments. Results of any such examination shall be made available to both Parties. REVIMMUNE shall bear the full cost of the performance of any such audit, unless such audit demonstrates underpayment of royalties by BIOVEST of more
than ten percent (10%) from the amount of the original royalty payment made by BIOVEST. In such event, BIOVEST shall bear the full cost of the performance of such audit. 
 ARTICLE 5—PATENT PROSECUTION; ENFORCEMENT; INFRINGEMENT 
  

	5.1	Patent Prosecution and Maintenance. 

 (a) Responsibility. The Parties hereby covenant, acknowledge and agree that the rights and responsibilities to prosecute and maintain any Patents licensed to REVIMMUNE pursuant to the JHU License shall be governed by the terms of the
JHU License. Biovest hereby assumes fifty percent of the cost and responsibility for patent prosecution of the licensed claims of Revimmune including but not limited to the Sublicensed Rights. 
 (b) Cooperation. Each Party agrees to cooperate with the other Party to execute any documents necessary or desirable to secure and
perfect the other Party’s legal rights and worldwide ownership in the other Party’s intellectual property, including, but not limited to documents relating to patent, trademark and copyright applications. Each Party agrees to take actions
reasonably necessary to diligently prosecute and maintain its intellectual property in major commercial markets where viable protection is available. Each party or its representatives shall be entitled to meet and confer with the other Party and
their patent counsel at reasonable times and places. 
  

	5.2	Limitations on Publications. The Parties agree that no one Party shall publish the results of any studies, whether conducted by its own employees or in conjunction
with a third party, carried out pursuant to this Agreement or confidential information received from the other Party that is relating to a Sublicensed Product, without the prior written approval of the other Party. Each Party agrees to provide the
other Party with a copy of any proposed abstracts, presentations, manuscripts, or any other disclosure which discloses clinical study results pursuant to this Agreement or confidential information received from the other Party at least sixty
(60) days prior to their intended submission for publication and agrees not to submit or present such disclosure until the Party not seeking to disclose such information provides its prior written approval. Such written approval will not be
unreasonably withheld unless such proposed disclosure could reasonably harm or impair a Party’s intellectual property assets or may reasonably cause commercial harm to a Party. 

  

	5.3	Notification of Infringement. If either Party learns of an infringement or threatened infringement by a third party of any Sublicensed Rights granted hereunder within the
Territory, such Party shall promptly notify the other Party and shall provide such other Party with available evidence of such infringement. Section 5.4 shall then be applicable. 

  

 9 

	5.4	Patent Enforcement. REVIMMUNE shall have the first right, but not the duty, to institute patent infringement actions against third parties based on any Sublicensed Rights
under this Agreement. If REVIMMUNE does not institute an infringement proceeding against an offending third party within ninety (90) days after receipt of notice from BIOVEST, BIOVEST shall have the right, but not the duty, to institute such an
action. The costs and expenses of any such action (including fees of attorneys and other professionals) shall be borne by the Party instituting the action, or, if the Parties elect to cooperate in instituting and maintaining such action, such costs
and expenses shall be borne by the Parties in such proportions as they may agree in writing. Each Party shall execute all necessary and proper documents and take such actions as shall be appropriate to allow the other Party to institute and
prosecute such infringement actions. Any award paid by third parties as a result of such an infringement action (whether by way of settlement or otherwise) shall be paid to the Party who instituted and maintained such action, or, if both Parties
instituted and maintained such action, such award shall be allocated among the Parties in proportion to their respective contributions to the costs and expenses incurred in such action. 

  

	5.5	Infringement Action by Third Parties. 

 (a) Claim or Suit Against BIOVEST. In the event of the institution of any claim or suit by a third party against BIOVEST for patent infringement involving the manufacture, use, or sale of any Sublicensed Product in the Territory,
BIOVEST shall promptly notify REVIMMUNE in writing of such claim or suit, However, BIOVEST shall have the right to defend such claim or suit at its own expense and REVIMMUNE hereby agrees to assist and cooperate with BIOVEST to the extent necessary
in the defense of such claim or suit. During the pendency of such claim or suit, BIOVEST shall continue to make all payments due under this Agreement, but shall have a credit against Sublicensed Royalty payments otherwise payable hereunder for the
full amount of all reasonable costs and expenses incurred by BIOVEST in defending against such claim or suit; provided, however, that in applying the credit against any royalty payments, the amount of such payment shall not be reduced by more than
50% and any remaining credit shall be applied against subsequent royalty payments. The cost and expense of any such claim or suit including but not limited to the cost of defense shall be shared equally by Revimmune and Biovest. 
 (b) Claim or Suit Against REVIMMUNE. In the event of the institution of any claim or suit by a third party against REVIMMUNE for
patent infringement involving the manufacture, use, or sale of any Sublicensed Product in the Territory covered by this Sublicense Agreement, REVIMMUNE shall promptly notify BIOVEST in writing of such claim or suit. REVIMMUNE shall have the right
but not the obligation to defend such claim or suit at its own expense and BIOVEST hereby agrees to assist and cooperate with REVIMMUNE, at BIOVEST’s own expense (provided that Revimmune shall reimburse BIOVEST for its out-of-pocket expenses),
to the extent necessary in the defense of such claim or suit. 
  

 10 

 ARTICLE 6—CONFIDENTIALITY 
  

	6.1	Use of Name. REVIMMUNE agrees not to use directly or indirectly BIOVEST’s name without BIOVEST’s prior written consent. BIOVEST agrees not to use directly or
indirectly REVIMMUNE’s name or information without REVIMMUNE’s prior written consent. Notwithstanding the foregoing, BIOVEST and REVIMMUNE may include an accurate description of the terms of this Agreement to the extent required under
federal or state securities laws or other disclosure; and BIOVEST may use REVIMMUNE’s names in various documents used by BIOVEST for capital raising and financing purposes. 

  

	6.2	Confidentiality; Exceptions. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, for the term of this
Agreement and for the longer of three (3) years thereafter or the termination of the JHU License, the receiving Party shall keep completely confidential and shall not publish or otherwise disclose and shall not use for any purpose other than
proper performance hereunder any information furnished to it by the other Party pursuant to this Agreement, except to the extent that it can be established by the receiving Party by competent proof that such information: 

 (a) was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the other
Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to
the receiving Party; 
 (c) became generally available to the public or otherwise part of the public domain after its
disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; 
 (d) was disclosed
to the receiving Party, other than under an obligation of confidentiality, by a Third party who had no obligation to the disclosing Party not to disclose such information to others; or 
 (e) was independently developed by or for the receiving Party by persons not having access to such information, as determined by the
written records of such party. 
  

	6.3.	Obligations of Employees and Consultants. The Parties each represent that all of its employees and the employees of its Affiliates, and any collaborators or consultants to
such Party or its Affiliates, who shall have access to confidential information of the Parties are bound by written obligations to maintain such information in confidence and not to use such information except as expressly permitted herein. Each
Party agrees to enforce confidentiality obligations to which its employees and consultants (and those of its Affiliates) are obligated. 

  

 11 

 ARTICLE 7—INDEMNIFICATION 
  

	7.1	Indemnification by BIOVEST. BIOVEST shall defend, indemnify and hold REVIMMUNE and JHU, their respective officers, directors, employees and consultants harmless from and
against any and all third party claims, suits or demands, threatened or filed, (“Claims”) for liability, damages, losses, costs and expenses (including the costs and expenses of attorneys and other professionals), at both trial and
appellate levels, relating to the distribution, testing, manufacture, use, sale, consumption on or application of Sublicensed Products by BIOVEST, its Affiliates or its sublicensees pursuant to this Sublicense Agreement, including, without
limitation, claims for any loss, damage, or injury to persons or property, or loss of life, relating to the promotion and advertising of Sublicensed Products and/or interactions and communications with governmental authorities, physicians or other
third parties relating to the Sublicensed Products. The foregoing indemnification shall not apply to any third party Claims to the extent are caused by the gross negligence of REVIMMUNE or, in the case of indemnification of JHU by JHU, and the
foregoing indemnification shall also not apply to any Claims that would give rise to a REVIMMUNE indemnification obligations pursuant to Section 7.1 below or pursuant to any other provision of this Agreement. 

  

	7.2	Indemnification by REVIMMUNE. REVIMMUNE shall defend, indemnify and hold BIOVEST, its officers, directors, employees and consultants harmless from and against any and all
third party Claims for liability, damages, losses, costs and expenses (including the costs and expenses of attorneys and other professionals), at both trial and appellate levels, relating to REVIMMUNE’s activities contemplated under this
Agreement, including, but not limited to, (a) breach of the representations, warranties and obligations of REVIMMUNE hereunder, or (b) any tax, duty, levy or government imposition on any sums payable by BIOVEST to REVIMMUNE hereunder. The
foregoing indemnification shall not apply to any Claims to the extent caused by the gross negligence of BIOVEST. 

  

	7.3	Notice. In the event that either Party seeks indemnification under Sections 7.1 or 7.2, the Party seeking indemnification agrees to (i) promptly inform the other Party
of the Third party Claim, (ii) permit the other Party to assume direction and control of the defense or claims resulting there from (including the right to settle it at the sole discretion of that Party), and (iii) cooperate as reasonably
requested (at the expense of that Party) in the defense of the Claim. 

  

	7.4	Insurance. Prior to the use of any Sublicensed Product in connection with a clinical trial or the first sale of a Sublicensed Product which ever occurs first, BIOVEST shall
obtain and maintain broad form comprehensive general liability insurance and products liability insurance with a reputable and financially secure insurance carrier, subject to approval by REVIMMUNE’s primary insurance broker, to cover such
activities of BIOVEST and BIOVEST’s contractual indemnity under this Agreement. Such insurance shall provide minimum annual limits of liability of $3,000,000 per occurrence and $5,000,000 in the aggregate with respect to all occurrences being
indemnified under this Agreement. Such insurance policy shall name REVIMMUNE as an additional insured and shall be purchased and kept in force for the period of five (5) years after the cessation of sales of all Sublicensed Products under this
Agreement. 

  

 12 

 ARTICLE 8—TERM; TERMINATION 
  

	8.1	Term. Unless earlier terminated under Section 8.2 hereof, this Agreement and the Sublicense granted hereby shall commence as of the Effective Date and, unless sooner
terminated as provided hereunder, shall have an initial term (the “Initial Term”) that shall terminate on the last to occur of: (i) Ten (10) years from the date hereof, (ii) the termination of the JHU License, or
(iii) the expiration of the last-to-expire of the patent claims included in the Sublicensed Rights. The Term shall be automatically extended by successive extension terms (the “Extension Terms”) of one (1) year each unless either
party gives written notice of its election not to extend the term at least ninety (90) days prior to the expiration of the Initial Term or of any Extension Term. Notwithstanding the forgoing, the Sublicense shall terminate upon the filing of a
petition in bankruptcy by or against Biovest or the filing of a petition for liquidation or receivership of Biovest. Notwithstanding the forgoing, the Sublicense shall terminate upon any pledge or granting of any lien or security interest in the
Sublicense or any interest under the Sublicense without the prior written consent of REVIMMUNE. Further, the Sublicense shall terminate in the event that BIOVEST does not file an IND which is accepted for filing by the Food and Drug Administration
for an indication which upon approval will result in royalties being paid to Revimmune under this Sublicense within two (2) years from the date hereof. 

  

	8.2	Breach. Failure by either Party to comply with any of the material obligations contained in this Agreement shall entitle the other Party to give to the Party in default
notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within one hundred twenty (120) days after the receipt of such notice (or, if such default cannot be cured within such 120 day
period, if the Party in default does not commence and diligently continue actions to cure such default), the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement, in addition to any other
remedies available to it by law or in equity, to terminate this Agreement by giving written notice to take effect within thirty (30) days after such notice unless the defaulting Party shall cure such default within said thirty (30) days.
The right of either Party to terminate this Agreement, as hereinabove provided, shall not be affected in any way by its waiver or failure to take action with respect to any previous default. 

  

	8.3	Termination of Sublicenses. Upon any termination of this Agreement, all sublicenses granted by BIOVEST under this Agreement shall terminate simultaneously, subject,
nevertheless, to Section 8.4. 

  

	8.4	Effect of Termination. Upon the termination of this Sublicense Agreement, BIOVEST and its sublicensees shall promptly: (i) return to REVIMMUNE all relevant records,
materials or confidential information of REVIMMUNE concerning the REVIMMUNE Licensed Rights relating to such Sublicensed Product in the possession or control of BIOVEST or its sublicensees; (ii) assign to REVIMMUNE, or REVIMMUNE’s
designee, its registrations with governmental health authorities, licensees, and approvals of such Sublicensed Product in the Territory and (iii) cease and desist from developing, promoting, marketing, selling or commercializing any Sublicensed
Product (except to the extent reasonably necessary to liquidate existing inventories and fulfill then-existing orders and obligations). 

  

 13 

	8.5	Surviving Rights. Termination of this Agreement shall not terminate BIOVEST’s obligation to comply with Articles 4, 5, 6 and 7 hereunder. 

  

	8.6	Accrued Rights, Surviving Obligations. Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights which shall have
accrued to the benefit of either Party under this Agreement prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve either Party from obligations which are expressly indicated to
survive termination or expiration of this Agreement. 

 ARTICLE 9—MISCELLANEOUS PROVISIONS 
  

	9.1	Relationship of Parties. Nothing in this Agreement is or shall be deemed to constitute a partnership, agency, employee or joint venture relationship between the Parties. No
Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. 

  

	9.2	Inter-relationships. REVIMMUNE and BIOVEST each acknowledge that a Hopkins Capital Group, LLC entity owns an equity interest in both REVIMMUNE and BIOVEST and that Frank
O’Donnell, MD is an affiliate and founder of the Hopkins Capital Group, LLC entities, REVIMMUNE and BIOVEST. BIOVEST represents that its Audit Committee and independent directors have been fully advised of these inter-relationships.

  

	9.3	Assignment. Except as otherwise provided herein, neither this Agreement nor any interest hereunder shall be assignable by BIOVEST without the prior written consent of
REVIMMUNE; provided, however, that either Party may assign this Agreement to any wholly-owned subsidiary or to any successor by merger or sale of substantially all of its assets to which this Sublicense Agreement relates in a manner such that the
assignor shall remain liable and responsible for the performance and observance of all its duties and obligations hereunder. This Sublicense Agreement shall be binding upon the successors and permitted assigns of the parties and the name of a Party
appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 10.3 shall be
void. Biovest shall not pledge or permit any lien or security interest to be placed against the Sublicense or any interest hereunder without the prior written consent of REVIMMUNE. Any pledge, lien or security interest not in accordance with this
Section 10.3 shall be void. 

  

	9.4	Further Actions. Each Party agrees to execute, acknowledge and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order
to carry out the purposes and intent of this Agreement. 

  

	9.5	 Force Majeure. Neither Party shall be liable to the other for loss or damages nor shall have any right to terminate this Agreement for any default or delay
attributable to any act of God, flood, fire, explosion, strike, lockout, labor dispute, shortage of raw materials, casualty, accident, war, revolution, civil commotion, act of public enemies, blockage or embargo, injunction, law, order,
proclamation, regulation, ordinance, demand or requirement of any government or subdivision, authority or representative of any such government, or any other cause beyond the reasonable control of such Party, if the Party 

  

 14 

	 	 
affected shall give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations
hereunder as it is thereby disabled from performing for so long as it is so disabled and for thirty (30) days thereafter. Notwithstanding the foregoing, nothing in this Section 10.5 shall excuse or suspend the obligation to make any
payment due hereunder in the manner and at the time provided. 

  

	9.6	No Trademark Rights. Except as otherwise provided herein, no right, express or implied, is granted by this Agreement to use in any manner the name “BIOVEST” or
“REVIMMUNE” or any other trade name or trademark of the other party in connection with the performance of this Agreement. 

  

	9.7	Public Announcements. Except as required by law, neither Party shall make any public announcement concerning this Agreement or the subject matter hereof without the prior
written consent of the other. In the event of a legally-required public announcement, the Party making such announcement shall provide the other with a copy of the proposed text prior to such announcement. 

  

	9.8	Notices. Any notice required or permitted to be given or delivered hereunder or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have
been properly served if: (a) delivered personally, (b) delivered by a recognized overnight courier service instructed to provide next-day delivery, (c) sent by certified or registered mail, return receipt requested and first class
postage prepaid, or (d) sent by facsimile transmission followed by confirmation copy delivered by a recognized overnight courier service the next day. Such notices, demands and other communications shall be sent to the addresses set forth
below, or to such other addresses or to the attention of such other person as the recipient Party has specified by prior written notice to the sending Party. Date of service of such notice shall be: (i) the date such notice is personally
delivered or sent by facsimile transmission (with issuance by the transmitting machine of confirmation of successful transmission), (ii) three days after the date of mailing if sent by certified or registered mail, or (iii) one day after
date of delivery to the overnight courier if sent by overnight courier. Unless otherwise specified in writing, the mailing addresses of the Parties shall be as described below: 

  

	 	(a)	If to REVIMMUNE, addressed to: 

 REVIMMUNE, LLC 
 324 South Hyde Park Avenue 
 Suite 350 
 Tampa, FL 33606 
 Attn: Managing Member 
  

 15 

	 	(b)	If to BIOVEST, addressed to: 

 BIOVEST
INTERNATIONAL, INC. 
 324 South Hyde Park Avenue 
 Suite 350 
 Tampa, FL 33606 
 Attn: CEO 
  

	9.9	Amendment. No amendment, modification or supplement of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized
officer of each Party. This Agreement may be executed in a series of counterparts, all of which, when taken together, shall constitute one and the same instrument. 

  

	9.10	Waiver. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly
waiving such provision and signed by the waiving Party. 

  

	9.11	Dispute Resolution. 

 (a) Senior
Officials. The Parties recognize that a bona fide dispute as to certain matters may from time to time arise during the term of this Agreement which relates to either Party’s rights and/or obligations hereunder. In the event of the
occurrence of such a dispute, either Party may, by notice to the other Party, have such dispute referred to their respective senior officials designated below or their successors, for attempted resolution by good faith negotiations within thirty
(30) days after such notice is received. Said designated senior officials are as follows: 
  

			
	For BIOVEST:	  	Chairman of the Audit Committee
	For REVIMMUNE:	  	Francis E. O’Donnell, Jr., M.D. Managing Member

 In the event the designated senior officials are not able to resolve such dispute within the
thirty (30) day period, either Party may invoke the provisions of Section 10.11(b). 
 (b) Arbitration. In
the event of any dispute, difference or question arising between the Parties in connection with this Agreement, the construction thereof, or the rights, duties or liabilities of either Party, and which dispute cannot be amicably resolved by the good
faith efforts of both Parties, then such dispute shall be resolved by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. The arbitration panel shall be composed of three arbitrators, one
of whom shall be chosen by REVIMMUNE, one by BIOVEST, and the third by the two so chosen. If both or either of BIOVEST or REVIMMUNE fails to choose an arbitrator or arbitrators within fourteen (14) days after receiving notice of commencement of
arbitration or if the two arbitrators fail to choose a third arbitrator within fourteen (14) days after their appointment, the then President of the American Arbitration Association shall, upon the request of both or either of the Parties to
the arbitration, appoint the arbitrator or arbitrators required to complete the board or, if he shall decline or fail to do 

  

 16 

 
so, such arbitrator or arbitrators shall be appointed by the American Arbitration Association. The decision of the arbitrators shall be by majority vote and,
at the request of either Party; the arbitrators shall issue a written opinion of findings of fact and conclusions of law. Costs shall be borne as determined by the arbitrators. Unless the Parties to the arbitration shall otherwise agree to a place
of arbitration, the place of arbitration shall be at Tampa, Florida, U.S.A. The arbitration award shall be final and binding upon the Parties to such arbitration and may be entered in any court having jurisdiction. 
  

	9.12	Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of FLORIDA. 

  

	9.13	Severability. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Agreement is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. 

 

	9.14	Entire Agreement of the Parties. This Agreement constitutes and contains the entire understanding and agreement of the Parties and cancels and supersedes any and all prior
negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof. 

 [NEXT PAGE IS THE SIGNATURE PAGE] 
  

 17 

 IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized
officer as of the day and year first above written. 
  

			
	 REVIMMUNE LLC

		
	 By:
	 	 /s/ Francis E. O’Donnell, Jr.

	 Name:
	 	Francis E. O’Donnell, Jr., M.D.
	 Title:
	 	Manager
	
	 BIOVEST INTERNATIONAL, INC.

		
	 By:
	 	 /s/ Steven Arikian

	 Name:
	 	Steven Arikian, M.D.
	 Title:
	 	Chairman and CEO

 EXHIBIT A 
 Johns Hopkins University License Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00135-of-00352.parquet"}]]